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i 
Abstract 
The main role of excipients is to ensure the safety and efficacy of the whole 
pharmaceutical formulation throughout its shelf-life and administration. Formulation 
design and development as well as material testing are the key components for successful 
drug delivery.  This is becoming increasingly complicated as new active pharmaceutical 
ingredients typically have poor solubility and/or bioavailability. Due to this, there is an 
ever increasing need to explore new excipients and material combinations as innovative 
formulation solutions are required. Furthermore, modified release formulations are needed 
to control the release rates and to adjust the desired therapeutic effects, raising even more 
demand for effective formulations.  
The main aim of this thesis was to evaluate the performance of plant based materials 
nanofibrillar cellulose (NFC) and anionic carboxylated nanofibrillar cellulose (ANFC) as 
pharmaceutical excipients for modified release formulations and bioadhesive films. These 
materials are widely available from renewable sources; biocompatible with relatively low 
toxicity combined with high mechanical strength and large surface area available for 
encapsulation.  
NFC and ANFC, together with HFBII protein, were used as emulsion stabilizers for 
encapsulation and release of poorly water-soluble drugs. The synergistic stabilization 
mechanism achieved with these biopolymers improved emulsions stability with extremely 
low concentrations. In another study, ANFC hydrogels were evaluated as matrix reservoirs 
for diffusion controlled drug release. Their rheological and drug release properties were 
shown to be preserved after freeze-drying and reconstruction. The ANFC hydrogels 
controlled the release kinetics of small molecular weight drugs moderately, whereas 
significant control was obtained in the case of large proteins. In a comparative study, three 
new grades of microcrystalline cellulose (MCC) hydrogels were evaluated for diffusion 
controlled drug release. MCC matrices efficiently controlled the release of both large and 
small compounds, indicating great potential for drug release applications in a similar 
manner to the ANFC hydrogels.  
Bioadhesive NFC and ANFC based films were prepared by incorporating bioadhesive 
polymers mucin, pectin and chitosan into the film structure. The bioadhesive properties of 
the films combined with good mechanical and hydration properties, together with low 
toxicity makes them a feasible option for buccal drug delivery applications. 
In conclusion, NFC and ANFC were shown to be versatile excipients applicable for 
several types of dosage forms. In the future, it is seen that these materials may be used 
systematically as functional excipients for modified release dosage form. 
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11 Introduction 
A medicine contains essentially two parts the active pharmaceutical ingredient (API) and 
suitable excipients that complete the total volume/mass of a given formulation. Excipients 
are defined by the International Pharmaceutical Excipients Council (IPEC) as substances 
in the pharmaceutical formulation other than the APIs [1]. Traditionally excipients have 
been considered as completely inert materials necessary for the manufacturing and storage 
as well as administration of uniform dosage forms of the API. However, nowadays it is 
acknowledged that excipients have a major role in the functionality, manufacturability and 
storage stability of a formulation. Pharmaceutical excipients have multiple functions such 
as ensuring stability by protecting API during manufacturing and storage, improving the 
dosing accuracy of API, improving bioavailability, masking of poor organoleptic 
properties and improving patient compliance [2]. The major function of any excipient is to 
ensure the safety and efficacy of the medicine throughout the formulation shelf-life and 
during and after the administration.  
Formulation design is becoming more complicated as new active molecules with poor 
solubility and high molecular weight are entering the product pipeline [3,4]. There is an 
ever increasing need for new pharmaceutical excipients as innovative formulation 
solutions are explored to facilitate the poor properties of existing and new API. Typically 
the oral administration route is the preferred drug delivery route for chronic therapy due to 
its high patient compliance and ease of administration when compared to the parenteral 
routes. However, the disease pathophysiology and the desired target determine the 
administration route in drug delivery. Other commonly used administration routes include 
topical, nasal and ocular routes. Formulation development and material testing are key 
components in successful drug delivery through the various administration routes. 
Furthermore, modified release formulations can be used to control the drug release rate 
and to adjust the desired therapeutic effect by means of formulation.  
Biopolymers offer an alternative to synthetic polymers as excipients in pharmaceutical 
dosage forms. Usually the use of biopolymers benefits from their relatively low toxicity as 
well as renewable abundant sources available for production. Natural polymer cellulose 
can be used as a starting material for the production of nanocellulose and microcrystalline 
cellulose. Nanocellulose is a relatively new emerging material in the field of 
pharmaceutics and biomedical applications. It has been explored for these applications due 
to its interesting properties such as high strength and stiffness combined with low weight, 
biocompatibility, high surface area and renewability [5].  
This thesis work focused on exploring the use of nanofibrillar cellulose (NFC) and anionic 
carboxylated nanofibrillar cellulose (ANFC) as pharmaceutical excipients in modified 
release formulations and bioadhesive films where the formulation in capable of controlling 
the drug release rate. So far relatively few studies have focused on exploring 
nanofibrillated cellulose as a pharmaceutical excipient. The main aim here was to 
investigate the applicability of NFC and ANFC in various modified release formulations. 
An additional aim of the thesis was to evaluate novel type MCC hydrogel dispersions in 
2controlled drug release applications. Moreover, we have used only biopolymers such as 
hydrophobin proteins, mucin, chitosan and pectin as additional excipients in all evaluated 
modified release formulations.  
Firstly, NFC and ANFC were used as emulsion stabilizers together with hydrophobin class 
II protein HFBII. Previously a combination of NFC and hydrophobin proteins has been 
used to stabilize emulsions [6]. However in the thesis the purpose was to evaluate the 
applicability of these emulsions for the encapsulation and release of poorly water-soluble 
BCS II class drugs. It was hypothesized that the nanocellulose grade would affect the drug 
release rate.
Secondly, concentrated ANFC hydrogels were introduced as matrix reservoirs for 
controlled drug delivery applications of small molecules and proteins. A further aim here 
was to study how the freeze-drying and subsequent rehydration of ANFC hydrogel affects 
the rheological and drug release properties. The aggregation of NFC fibers during drying 
is a major manufacturing challenge in the production of dry NFC as the nanoscale 
dimensions are usually lost [7,8]. It was hypothesized that ANFC grade together with 
commonly used lyoprotectants would be a more suitable combination in terms of 
preserving the nanoscale dimensions in the reconstructed hydrogels after drying. Further it 
was hypothesized that the anionic nature and high viscosity of ANFC matrix could be 
used to control the drug release rates of several small and large molecular weight model 
compounds.  
Thirdly, three types of microcrystalline cellulose (MCC) hydrogel dispersions were 
evaluated for controlled drug release application. Typically MCC is used as an excipient in 
the dry form. Here, however a novel type of manufacturing process enabled the use of 
MCC as highly concentrated colloidally stable hydrogel dispersions. It was hypothesized 
that the rheological properties as well as colloidal stability and porosity could be used to 
control the drug release rate in a sustained manner in comparison to commercial MCC 
Avicel grades. 
Furthermore, mucoadhesive NFC and ANFC films were prepared. NFC and ANFC were 
used as film forming materials and natural mucoadhesive biopolymers mucin, pectin and 
chitosan were incorporated into the films to add bioadhesive functionality without further 
chemical modification of the NFC and ANFC structures. It was hypothesized that 
effective mucoadhesive properties, suitable mechanical properties in combination with 
low toxicity and relatively fast drug release desirable for a buccal type dosage form could 
be obtained.  
The literature review part of this thesis will focus on the properties and pharmaceutical 
applications of cellulose, nanofibrillar cellulose and microcrystalline cellulose. 
Fundamental aspects on the topics of modified release and mucoadhesive drug delivery 
systems as well as freeze-drying of pharmaceuticals are covered. After the literature 
review, the aims of the thesis and materials and methods are introduced. Finally, the 
obtained results are presented and the findings are discussed. 
32 Review of the literature 
2.1 Cellulose  
Cellulose was first discovered and isolated from green plants by a French chemist 
Anselme Payen in 1838 [9]. Today, cellulose is one of the most important renewable 
biopolymers on earth and for industrial scale manufacturing it provides a key source for 
the production of sustainable materials [10,11]. Wood (hardwood, softwood) and cotton 
are the major sources for commercial cellulose production, however other plant based 
materials such as seed fibers, bast fibers (hemp, jute, flax), grasses (bamboo, bagasse) as 
well as algae (Valonica ventricosa) and bacteria (Gluconacetobacter xylinum, Acetobacter 
xylinum) can be used as sources for production [12]. In plants cellulose is a component of 
the cell wall and it has a reinforcing role together with hemicelluloses, pectin and lignin 
[13,14].  
Structurally cellulose is a linear polysaccharide homopolymer that consists of β(1→4) 
linked D-glucopyranose units, the so-called anhydroglucose units (AGU) (Figure 1) [15].
Every second AGU unit is rotated 180° in plane for the formation of an acetal bond 
between two adjacent AGU units, and the neighboring cellulose monomers form a dimer 
called cellobiose [16]. The length of cellulose chains, found in nature, vary greatly 
depending on the degree of polymerization (DP). Typically in wood cellulose the chain 
consists of 10000 AGU units, whereas native cotton cellulose consists of 15000 AGU 
units [17]. Each glucose unit has three hydroxyl groups available for hydrogen bonding 
and chemical modifications positioned at C-2, C-3 and C-6 atoms. Intra-and 
intermolecular hydrogen bonds form various types of semicrystalline structures due to the 
uniform distribution of hydroxyl groups [18]. Cellulose has reportedly six different 
polymorphs (I, II, IIII, IIIII, IVI, IVII) with the possibility of conversion from one form to 
another [11]. Native cellulose from plant origin constitutes from form I cellulose with two 
allomorphs Iα and Iβ [19,20]. The origin of cellulose affects the ratio of Iα and Iβ 
(predominant in higher plants). Iα exhibits triclinic type of unit cells and is a metastable 
form, whereas Iβ has monoclinic type of unit cells [21].
Figure 1. Molecular structure of cellulose that is composed of repeated anhydroglucose 
(AGU) units [15]. 
Individual cellulose chains aggregate to form long threadlike microfibrils (elementary 
fibrils) that are laterally stabilized by hydrogen bonds between hydroxyl groups and 
4oxygens of adjacent molecules [22,23]. The diameter of microfibrils ranges between 3-35 
nm depending on the origin [24]. Each microfibril contains a string of crystalline regions 
linked by amorphous domains. Microfibrils bundle together further to form cellulose 
fibers, and in wood based cellulose the microfibrils are surrounded by an amorphous 
matrix of lignin and hemicelluloses [17]. Lignins are water insoluble amorphous polymers 
consisting of phenylpropane units without an ordered and regular structure [25]. In wood 
based cellulose, hemicelluloses crosslink cellulose fibrils in a lignin matrix. 
Hemicelluloses, such as xylan and glucuronoxylan, are a group of heteropolysaccharides 
present along with cellulose in almost all plant cell walls [14]. Due to the supramolecular 
structure of cellulose it is insoluble in water as well as in common organic solvents [24]. 
The structural properties and organization within plants affects the self-assembly and 
organization of cellulose based materials in manufactured products. Due to low cost, 
biodegrability (in nature), renewable source, good biocompatibility and low toxicity, 
cellulose based materials are used as excipients in pharmaceutical dosage forms [24,26]. 
Several chemical modifications altering the hydrophilicity of cellulose structure are 
possible [15]. Cellulose derivatives such as microcrystalline cellulose (MCC) and water 
soluble hydroxypropyl (HPC), hydroxypropylmethyl (HPMC) and 
carboxymethylcellulose (CMC) are all commonly used excipients in the pharmaceutical 
industry. Among these, MCC is the most frequently used excipient with various uses 
ranging from tablet binder and diluent in direct compression or wet granulation to tablet 
disintegrant, anti-adherent or capsule diluent [26]. On the contrary, nanofibrillar cellulose 
is a new emerging material in the biomedical field and extensive research has been 
focused in recent years on various biomedical applications. Whereas controlled drug 
release applications have been investigated to a lesser extent. 
2.2 Nanofibrillar cellulose  
The term nanocellulose refers to three types of materials: (I) nanofibrillar cellulose (NFC), 
also referred to as cellulose nanofibrils, microfibrillated cellulose, nanofibrillated cellulose 
or nanocellulose fibers, (II) cellulose nanocrystals, also referred to as cellulose 
nanowhiskers and nanocrystalline cellulose, and (III) bacterial cellulose [27]. In the 
experimental part of this thesis modified release and mucoadhesive formulations were 
prepared from wood based native NFC and anionic type carboxylated NFC (ANFC). 
Therefore, the contents of the following literature review chapters will focus on the 
production, properties and pharmaceutical as well as biomedical use of NFC and ANFC. 
Cellulose nanocrystals and bacterial cellulose are excluded from the literature review. 
2.2.1 Production and morphology 
During late 70s and early 80s the manufacturing of NFC via mechanical treatment was 
pioneered by Sandberg et al. at ITT Rayonier Inc. in USA [28,29]. The mechanical 
treatment is used to delaminate cellulose fibers and liberate around 2-20 nm wide 
microfibrils. The microfibrils have a high aspect ratio and gel-like properties in water. 
Major challenge for commercial NFC production with mechanical disintegration 
5techniques used to be the extremely high energy consumption up to 70000 kWh per ton 
[30]. However, technology advances and development of different mechanical, biological 
and chemical pretreatments prior to the principal mechanical treatment has reduced the 
energy consumption making the commercialization of NFC possible [31]. Several 
companies, such as UPM (Finland), American Process Inc. (USA), Daicel FineChem Ltd. 
(Japan) and Innventia (Sweden) nowadays have a commercial NFC product in their 
portfolio.  
Never-dried and once-dried cellulose are both used as a starting material for NFC 
production. However the fibrillation process in less energy consuming with the never-
dried material, since drying promotes irreversible hydrogen-bonding between nanofibrils, 
known as hornification [7,32]. Wood pulp is a commonly used starting material for NFC 
production. Accompanying hemicelluloses and lignin need to be removed from NFC by 
various cooking and bleaching methods prior to fibrillation, nevertheless some residual 
amounts usually remain in the final wood based NFC [33]. Hemicellulose contains 
carboxyl groups, and wood based NFC fibers carry an anionic charge due to the residual 
hemicellulose coating on the surface of the fibers [34]. NFC isolation from wood requires 
that the highly organized hierarchical structure is mechanically disintegrated. Non-wood 
plants usually contain less lignin and the fiber delignification and purification processes 
are therefore less demanding [35]. Also, the fibrillation process of such material is less 
demanding as the cellulose microfibrils are less tightly bound than in the secondary cell 
wall of wood [36]. Up to date the production of NFC from for example potato pulp 
[37],sugar beet pulp [38], soybean ponds [39], rice straw [40], pineapple leaf [41], banana 
[42], sisal fibers [43] and oat straw [44] has also been reported. 
Figure 2 contains a schematic presentation of different possible steps used in the 
production and isolation of NFC including purification, pretreatments, principal 
mechanical treatment and post-treatment modifications [31]. Usually the NFC production 
process includes several different operations and the final end product properties such as 
morphology [45], surface chemistry [46], crystallinity [47] and DP [48] depend on the 
overall process. Mechanical pretreatments such as blending [40], refining [49] and 
grinding [50] are used to reduce the cellulose fiber diameter prior to the principal 
mechanical treatment where microfibrils are exposed. All of the aforementioned 
techniques can be used as the sole mechanical treatment for NFC production if repeated 
adequately. Biological and chemical pretreatments are also available to reduce the energy 
consumption during NFC fibrillation. Enzymatic hydrolysis can be used to reduce the 
degree of polymerization [48]. The surface of NFC can be activated to produce ANFC that 
contains carboxyl groups directly on the fiber surface for example through TEMPO 
[(2,2,6,6-Tetramethylpiperidin-1-yl)oxyl] oxidation [45,51]. Other common chemical
pretreatments that render an anionic charge to the fiber surface include 
carboxymethylation [52] and sulfonation [53]. On the other hand, quaternization can be 
performed to cationize cellulose prior to fibrillation [54].
6Figure 2. Schematic presentation of NFC production process steps divided into 
purification, pretreatments (mechanical, biological, chemical), mechanical treatment and 
post-treatment modification [31]. 
The principal mechanical treatments available for NFC fibrillation include 
homogenization [55], grinding [50], refining [49], extrusion [56], blending [40],
ultrasonication [57], cryocrushing [38], steam explosion [41], ball milling [58] and 
aqueous counter collision [59]. After the mechanical fibrillation, further chemical 
modifications [60] and fiber fractioning [61] are possible. The diameter of native NFC 
fibers is typically 5-60 nm with a length of several micrometers [62]. The NFC fiber 
dimensions, hemicellulose content, surface chemistry and the quantities of crystalline and 
amorphous regions may vary depending on the origin of cellulose raw material as well as 
nanofibrillation processing [5,62]. TEMPO oxidized ANFC fibers have an anionic surface 
charge, 3-4 nm diameter and the length in the range of few micrometers [45,51]. 
2.2.2 Rheological and mechanical properties 
NFC and ANFC are typically produced as aqueous hydrogel suspensions [62]. Both 
grades NFC and carboxylated ANFC, are highly hydrophilic materials with a high water 
binding capacity and high fiber surface area (due to the high aspect ratio). The abundant 
hydroxyl groups (-OH) on the surface of NFC favor the hydrogen bonding between 
adjacent NFC fibers. This results in natural self-assembly in an aqueous environment, and 
in the formation of a hydrogel structure due to the hydrogen bonding between fibers and 
the high entanglement of NFC fiber network [63]. However, the colloidal stability of NFC 
suspensions arises from electrostatic repulsion between fibers as the fibers have a slightly 
anionic surface charge caused by the residual hemicellulose coating (which contains a lot 
of -COOH groups) on top of NFC fibers [34]. Due to multiple reactive hydroxyl (-OH) 
groups on the surface of native NFC several chemical modifications are possible [12,60]. 
TEMPO oxidation can be used to activate NFC surface, and to produce carboxylated 
ANFC where anionic (–COOH) groups are directly present on the fiber surface [45].
7In an aqueous environment, there is electrostatic repulsion present between adjacent 
ANFC fibers due to surface -COOH groups [64]. The repulsion forces improve the 
colloidal stability of ANFC suspensions [51]. Both grades (NFC and ANFC) have 
concentration dependent viscosity and exhibit the behavior of a pseudoplastic gel under 
increased shear rate as the shear thinning phenomenon is observed [63,65-67]. Cationic 
crosslinkers such as divalent Ca2+, Zn2+, Cu2+ and trivalent Al3+ and Fe3+ have been used 
to crosslink carboxylated ANFC and to modify the rheology of the material [68,69]. These 
modifications can be used to alter for example the viscosity and stiffness of the ANFC 
material without increasing the solid content of ANFC fibers in the hydrogel. The 
rheological properties of NFC and ANFC have enabled the use of these materials as 
stabilizers and viscosity modifiers in suspensions [70-72] and emulsions [6,73,74] in food 
technology, pharmaceuticals and cosmetics.
Cellulose nanofibrils (NFC and ANFC) have excellent mechanical properties combined 
with relatively low density and high surface area [75]. Upon drying, NFC fibers aggregate 
irreversibly due to a mechanism called hornification [7,8]. Here the irreversible fiber 
aggregation is caused by hydrogen bonds that are formed between adjacent NFC fibers 
when water is removed. Once dried, NFC fibers cannot be redispersed in water again. This 
property has been exploited for example in the production of: 1) films with Young’s 
modulus values between 6 - 13 GPa where the film porosity and preparation affect greatly 
the elastic properties [76,77], 2) flexible and deformable aerogels with hierarchical porous 
structures (98% porosity) and low density (0.02 g/cm3) [78] and 3) spray dried powders 
with low density and weight [79,80]. Interestingly, ANFC is less affected by hornification 
in terms of redispersability. It has been reported that ANFC can be redispersed after 
drying as the -COOH groups seem to act as a barrier against hornification reversing the 
process upon rehydration [81]. ANFC has also been used to produce films [82] as well as 
aerogels [83].
Cellulose nanofibrils in plants have a high elastic moduli of 140 - 150 GPa and possess 
high aspect ratios of over 250 [84,85]. The high stiffness is caused by the firmly bonded 
individual fibers present in a hierarchical alignment order. The hierarchical alignment is 
lost when the material is fibrillated to form NFC or ANFC. Up to date the alignment of 
individual nanofibrillated fibrils during drying has not been achieved for films, aerogels 
and powders as the alignment of the fibrils is limited by their physical dimensions [85].
Thus the mechanical strength of these dry forms is reduced significantly when compared 
to the potential of natural cellulose nanofibrils in plants. Nevertheless, the mechanical 
properties of NFC after fibrillation are still excellent as elastic modulus of 29 - 36 GPa 
[86] and tensile strength of 1 - 3 GPa [87,88] have been proposed for individual fibers. 
The elastic modulus values between 120 - 220 GPa have been reported for native cellulose 
crystals [89,90] and therefore NFC also possesses high toughness. Due to excellent 
mechanical properties NFC has been studied as a strengthener for composite materials 
[75]. In the composite approach the controlled alignment of the fibrils to a certain extent 
has been achieved resulting in the greater harnessing of the innate mechanical strength of 
NFC and ANFC fibrils [85].
82.2.3 Pharmaceutical and biomedical applications 
Cellulose is considered to be biocompatible due to moderate, if any, foreign responses in 
vivo [91,92]. Both grades, NFC [93-95] and ANFC [94,96], have also been shown to be 
biocompatible and nontoxic in several in vitro cell models, making them appealing for 
pharmaceutical and biomedical applications [5,97]. NFC hydrogels have been investigated 
widely in biomedical field, such as in implantable drug delivery [98], cell carrier systems 
attached to surgical sutures [99], cell encapsulation [100] and scaffold synthesis [101].
Furthermore, NFC hydrogel is also a suitable cell culture scaffold material for HepG2 and 
stem cell differentiation and three dimensional cell culturing [65,102-104]. In the dry state 
NFC films have been used in wound healing applications to promote skin regrowth in skin 
graft donor sites treatment [105]. 
Only a few studies have focused on the use of NFC or ANFC as a pharmaceutical 
excipient in modified release drug delivery formulations. Valo et al. have [71,106] used 
NFC for stabilization of nanoparticles. They showed that nanoprecitation of itraconazole 
in the presence of a surface active and genetically engineered hydrophobin fusion protein 
HFBI coupled with two cellulose binding domains could be used to create a functional 
coating on the surface of itraconazole nanocrystals [71]. The protein was used to facilitate 
binding of the nanoparticles to NFC matrix which increased the storage stability of the 
suspensions both before and after freeze-drying. Furthermore, the in vivo performance of 
the itraconazole was increased due to increased dissolution rate of itraconazole resulting 
from the decreased particle size of itraconazole. Valo et al. [106] further showed that the 
drug release rate of beclomethasone dipropionate nanoparticles embedded in a NFC 
aerogel could be tuned depending on the NFC aerogel origin. Four different NFC aerogels 
with embedded nanoparticles were evaluated. Drug release was immediate from red 
pepper and microcrystalline cellulose aerogels, whereas sustained release profiles were 
obtained with bacterial cellulose, quince seed and TEMPO-oxidized birch cellulose-based 
aerogels. It was clearly shown, that the structure of the aerogel and the interactions 
between nanoparticles and cellulose determined the drug release rate. 
Kolakovic et al. have explored NFC as a pharmaceutical excipient in tablets [107], spray-
dried microparticles [108] and sustained release films [109]. As a tableting excipient the 
spray-dried NFC nanofibers were successfully used with paracetamol for direct 
compression and tableting after wet granulation [107]. The tablet disintegration and 
dissolution studies showed an immediate drug release comparable results to “golden 
standard” direct compression excipient microcrystalline cellulose based tablets. Opposite 
to this, the spray-dried NFC microparticles with an average diameter of 5 μm showed a 
sustained drug release profile for over 60 days for encapsulated drugs [108]. Here it was 
shown that NFC microparticles can sustain drug release by forming a tight fiber network 
that limits drug diffusion from the system. Also the NFC films, produced with a filtration 
method and a high drug loading capacity between 20% and 40%, had a sustained drug 
release profiles close to zero-order kinetics for indomethacin, itraconazole and 
beclomethasone up to 3 months [109]. The control for drug release was here provided by
9the NFC films as the film sustains the drug release due to a tight fiber network around the 
incorporated drug crystals. Finally, the drug interactions with NFC films have also been 
explored by Kolakovic et al [110] with model drugs of different structural characteristics 
(size, charge, etc.). Here it was shown that the model drugs did bind to NFC films in a pH 
dependent manner and the main binding mechanism could be characterized as electrostatic 
forces.  
Crosslinked ANFC nano- and microgels have been proposed by Masruchin et al. [69] for 
the encapsulation and sustained release of small molecule drugs. Here the internal 
structures of the hydrogels, namely porosities, and swelling behavior were modified with 
cations (H+, Ca2+, Al3+), which in turn had a significant impact on drug release profiles. It
was suggested that drug release could be controlled by altering the internal structure of 
ANFC hydrogels during preparation. Also Weishaupt et al. [111] have exploited he 
negatively charged carboxyl groups on the surface of ANFC fibers as binding sites for 
various macromolecules such as peptides and enzymes. In essence, ANFC can act as a 
high-density carrier which enables the immobilization of drugs and macromolecules by 
electrostatic interactions. 
The publications highlighted above are a selected collection of research focused on NFC 
and ANFC use in the pharmaceutical and biomedical field. The main focus of this thesis 
work was to explore the potential of NFC and ANFC as excipients in pharmaceutical 
modified release formulations and expand the use of NFC and ANFC. The unique 
structural properties, high biocompatibility and low toxicity of these materials are all in 
favor of using them as novel pharmaceutical excipients.  
2.3 Microcrystalline cellulose  
MCC is used in pharmaceutical, food, polymer composite and cosmetics industries due to 
its renewability, economic value, non-toxicity, biodegrability, mechanical properties, high 
surface area and biocompatibility [112,113]. The following two chapters will give a short 
overview of MCC production techniques and properties as well as typical use in 
pharmaceutical applications.
2.3.1 Production and properties 
MCC is obtained from purified and partially depolymerized α-cellulose precursor. As 
described in the chapter regarding cellulose structure the α-cellulose microfibrils consist of 
crystalline and amorphous regions at nanometer range [22-24]. The crystalline regions 
comprise tight bundles of microcrystals formed by cellulose chains due to hydrogen 
bonding and van der Waals interactions.  In the preparation of MCC, the amorphous mass 
is removed from the microfibril structure [112]. It is possible to prepare MCC by treating 
α-cellulose with different processes such as acid hydrolysis [114,115], reactive extrusion 
[116], enzyme mediated depolymerization [117] or steam explosion [118,119]. When 
microfibrils are subjected to acid hydrolysis the amorphous regions are readily hydrolyzed 
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resulting in the production of shorter and crystalline fragments of MCC [114,115].
Typically MCC surface has a slight negative charge due to hydroxyl residues. By means 
of processing, the DP of the cellulose chain can be reduced with negligible weight loss. 
For MCC, the DP is typically less than 350 glucose units and the material has a high 
degree of crystallinity between 55 % - 80 % range [120].  
After the removal of amorphous regions and filtration the neutralized MCC slurry is 
typically spray-dried to a pure fine particle size MCC powder or alternatively co-
processed with a water-soluble polymer to obtain a colloidal suspensions form [112]. 
MCC suspensions are thixotropic and shear-thinning the extent however differs depending 
on raw material and MCC preparation method [121]. Avicel® was the first 
commercialized MCC grade in 1962 [122]. Nowadays, several commercial MCC grades 
are readily available with for example different particle sizes, densities, porosities, 
hydration swelling capacities, compressibility, moisture sorption capacity and mechanical 
properties.  
Recently, a new MCC grade named AaltoCell™ has been produced from never dried 
cellulose pulp under scalable conditions [123]. As the cellulose material remains undried 
during the processing, the resulting MCC material is more porous (due to lack of 
hornification) [124] and the cellulose matrix remains water-swollen. Furthermore, the 
production process of this new MCC grade has been deemed as environmentally 
sustainable and the processing conditions enable the adjustment of solid cellulose content 
in the dispersions [123]. 
2.3.2 Pharmaceutical applications 
MCC is the most frequently used cellulose based pharmaceutical excipient and it can be 
used in the manufacturing of several dosage forms. Generally MCC is considered to be the 
diluent with the best binding properties and it is one of the preferred binders in direct 
compression of tablets [125]. MCC also has self-disintegrating properties which can be 
utilized together with superdisintegrants to promote fast disintegration of tablets [126]. In 
wet granulation process MCC is useful as a binder [127]. 
MCC is also applicable for the stabilization of emulsions, suspensions, and foams [113]. 
In emulsions and suspensions the stabilization is achieved through thickening and 
viscosity enhancement or steric hindrance. The amphiphilic nature useful for emulsion 
stabilization arises from the presence of the free hydroxyl groups on the MCC surface that 
acts as hydrophilic points, whereas the crystalline portion functions as the hydrophobic 
domain [128,129]. MCC can also be used in combination with other cellulose derivatives 
to provide suspension stabilization. For example, Dan et. al [130] have used MCC mixed 
with CMC sodium (MCCS) as a dispersant for the spray-drying of drug suspension. The 
study showed that MCCS prevented the aggregation of drug nanoparticles in the 
suspension state, agglomeration during spray-drying process and furthermore enabled fast 
redispersability of the suspension.  
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Up to date MCC has been used extensively as an excipient in various pharmaceutical 
formulations. However, MCC is mostly used as the dried powdered form for tablet 
production or used in combination with other excipients in emulsion or suspension 
stabilization. So far, the use of the new MCC grade AaltoCell™ as a pharmaceutical 
excipient has not been reported. This thesis has aimed at exploring the use of concentrated 
MCC hydrogel dispersions (AaltoCell™) as platforms for controlled drug release 
applications. The hydrogel-like properties of these dispersions in addition to the enhanced 
colloidal stability of the new MCC material may be of use as a drug release rate 
controlling matrix in the hydrated state as currently the majority of commercial Avicel 
grades are better suited as excipients for pharmaceutical formulations in the dry state. 
2.4 Modified release systems  
In the literature, the term modified-release drug product is used to describe products that 
can alter the timing and/or the release rate of a drug compound [131]. Several types of 
drug products with different drug release characteristics can be defined under the term 
modified-release (Table 1). Based on the drug release characteristics of the products 
multiple different terms can be used to define and describe the various types of modified 
release products. Extended-release, delayed-release, targeted-release and orally 
disintegrating tablets can all be defined as modified-release drug products. The 
physicochemical, pharmacokinetic and pharmacodynamic properties of a drug compound 
as well as the properties of other materials used to formulate the dosage form define the 
basis for the design of modified-release formulations for different drug administration 
routes.  
Table 1. Drug release characteristics of modified release drug products [131].   
Modified release 
drug products Mode of action Drug release characteristics
Extended-release
(ER)
At least a twofold reduction in 
dosage frequency compared to 
conventional dosage form
Controlled-release (CR)
Sustained-release (SR)
Long-acting drug products
Delayed-release
(DR)
A time delay in the drug release 
after administration, after which 
the dose is released
Delayed-release of the dose 
due to e.g. enteric-coating
Targeted-release Drug release at or near the physiological target
Either immediate-
or extended-release
Orally 
disintegrating
tablets
Rapid disintegration in the saliva 
present at oral cavity Immediate release
  
By definition, controlled-release formulations belong as a subgroup to the wider group of 
modified-release formulations. Controlled release drug delivery systems provide temporal
and/or spatial control of drug release in the human body [132]. Additionally these systems 
may protect the drug from undergoing degradation or elimination under physiological 
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conditions. Figure 3 shows the effect of drug release profiles of conventional, sustained 
and zero-order controlled release on drug plasma concentration [133]. The therapeutic 
window of drug therapy lies between minimum effective concentration and minimum 
toxic concentration. Conventional single dosing of a tablet or intravenous injection may 
results initially for an elevated plasma concentration followed by a fast decrease in drug 
concentration below the therapeutic range. On the contrary, extended release systems can 
be utilized to adjust the plasma drug concentration within the therapeutic window with 
less fluctuation for a prolonged duration of time. Extended release (ER) formulations 
include sustained release (SR) and controlled release (CR) dosage forms. The difference 
between these two lies in the control of drug release rate. For a SR formulation the drug
release is maintained over a sustained period, whereas from a CR formulation the drug 
release rate is kept constant over a sustained period. Overall, the goal with these 
formulations is to improve patient compliance and efficacy of drug therapy with reduced 
side-effects. 
Figure 3. Simplified schematic of different drug release profiles [133]. Figure modified 
from reference.
A significant effort has been focused on developing different controlled and modified 
release technologies over the past 40 years [133]. Polymeric material is often the 
component that controls drug delivery and is usually the key ingredient in controlled 
release formulations [134,135]. Controlled release drug delivery systems have been 
classically divided in to the following four types based on the technique that regulates the 
drug release profile: a) pre-programmed rate, b) activation modulated, c) feedback 
regulated and d) site targeted [136].  
Delivery systems with a pre-programmed release profile have a predefined specific release 
rate for the cargo. The drug release rate may be defined with several parallel mechanisms 
such as wetting of the system, porosity of the system, water diffusion into the system, drug 
dissolution followed by diffusion, osmotic effects, polymer swelling and/or degradation 
and drug-excipient interactions [137,138]. Generally the mechanisms that are controlling 
the drug release from pre-programmed release systems include diffusion, swelling (water 
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penetration) or chemical control (erosion of polymer matrix), and the slowest process 
defines the overall drug release from the device [132,134].
Activation modulated systems require an internal or external stimuli for drug release to 
occur. Extensive research has been focused on triggers such as pH changes [139], light 
exposure [140], magnetic field [141], temperature changes [142] and exposure to enzymes 
[143]. Feedback-regulated systems are capable of self-regulating and adjusting the release 
according to the cues from physiological environment. Up to date e.g. carbon dioxide 
responsive [144] and glucose sensitive systems [145,146] have been explored. Site 
targeted systems are ideally capable of precise spatial control into the desired 
physiological target site. The development of these systems has been explored especially 
in cancer therapy where the efficacy of the treatment with minimal side-effects to healthy 
tissues is of utmost importance [147,148]. 
In the experimental part of this thesis, the potential of NFC and ANFC as drug release rate 
controlling polymers was explored in several modified release formulation types such as 
emulsions, hydrogels and mucoadhesive films. In the emulsions, the fibers in the 
continuous aqueous phase were used to encapsulate the oil phase droplets that contained 
the poorly water-soluble drugs. The ability of different cellulose fiber grades to control the 
drug release rate was evaluated. Potentially these emulsions could be used to solubilize 
effectively poorly-water soluble drugs and to provide tunable drug release characteristics 
in the gastrointestinal tract. In the hydrogel formulations, ANFC as well as MCC were 
evaluated as matrices for diffusion controlled drug release applications. ANFC hydrogels 
consist of a fiber network, whereas MCC hydrogel dispersions consist of a network of 
individual MCC particles. The hydrogel structure itself can be thought of as matrix type 
release rate controlling barrier. The mucoadhesive NFC/ANFC films were designed to be 
used in location-specific applications, where the drug release will occur at the oral 
mucosal membrane. Here the NFC/ANFC films were used for drug encapsulation and as 
platforms for the bioadhesive functionality imparted by mucoadhesive biopolymers. 
Diffusion was the main release mechanism in all the explored formulations throughout 
this thesis. The following chapter will describe the fundamentals of diffusion controlled 
drug delivery systems in more detail. 
2.4.1 Diffusion controlled drug delivery systems 
Diffusion is a mass transport process, where the net movement of molecules, ions or 
atoms occurs from a high concentration region to low concentration region against a 
concentration gradient. Diffusion has a significant role for drug release in most controlled 
drug delivery systems [137]. For diffusion controlled systems, other mass transport 
systems do not affect the drug release rate or the impact of other mechanisms can be 
considered negligible. The systems can be classified based on the physical structure as 
well as the ratio of initial drug loading to drug solubility. Figure 4 demonstrates diffusion 
controlled drug delivery systems that can be divided as reservoir devices and matrix 
systems. Based on the geometry of the device, mathematical equations for each type of 
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system can be used as tools for quantitative prediction of drug release mechanism, effect 
of formulation and processing [149,150]. The desired drug release profile can be achieved 
with the understanding of optimal formulation, device composition and manufacturing 
process.  
Figure 4. Schematic presentation of diffusion controlled reservoir and matrix type drug 
delivery systems [151]. The dots indicate completely dissolved drug molecules whereas 
the circles non-dissolved drug particles. Abbreviations: cini = initial drug concentration, cs
= drug solubility.
2.4.1.1 Reservoir devices 
For reservoir devices, the molecularly dispersed drug within the core and the release rate 
controlling barrier material in the shell are completely physically separated [151]. For 
non-constant activity source devices the initial concentration of drug (cini) in the core does 
not exceed drug solubility (cs) and there is no excess drug present in the core. The released 
molecules are not replaced over time and first order release kinetics is obtained for all 
geometries (slab, sphere and cylinder) with an exponentially decreasing release rate. For 
constant activity source devices the initial concentration of drug in the core does exceed 
drug solubility and there is an excess amount of drug present in the core. The released 
molecules are replaced as there is a saturated drug solution present in the core. Due to this, 
the drug concentration at the inner membranes surface remains constant and zero-order 
release kinetics is obtained as the cumulative amount of released drug increases linearly 
over time.  
2.4.1.2 Matrix systems 
In matrix systems, the drug and the release rate controlling material are distributed evenly 
throughout the device [151]. Based on initial drug loading to drug solubility ratio these 
systems can be divided as monolithic solutions and monolithic dispersions.  
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Monolithic solutions 
In monolithic solutions (cini ˂ cs) the drug is rapidly completely dissolved upon water 
penetration as the initial drug concentration is below solubility. Fick’s second law of 
diffusion can be solved for each geometry (slab, sphere and cylinder), which can be useful 
if it is necessary to calculate the cumulative drug release over time [151,152]. Also, if a 
parameter such as diffusion coefficient in a specific polymer matrix is unknown the 
equations can be fitted to experimental data. For thin films with negligible diffusional 
mass transport through the edges (slab geometry) of the film compared to diffusion 
through the main surface of the film Equation 1 can be used [153]:
Monolithic solutions with slab geometry (Eq. 1):  
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where Mt and M∞ signify the cumulative amounts of drug released at time t and infinite 
time ∞, D is the diffusion coefficient of the drug within the matrix system and L
represents the thickness of the film. Alternatively early times (Mt/M∞ ≤ 0.6) and late times 
(Mt/M∞≥ 0.4) approximations depicted by Equation 2 and 3 may be used [151]: 
Early times: 
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Monolithic dispersions 
In monolithic dispersions (cini ˃ cs) an excess amount of drug is present in relation to 
solubility. As water penetrates into the system the drug is only partially dissolved and 
therefore dissolved and non-dissolved drug is present in the matrix during drug release. 
The classical Higuchi equation (Eq. 4) can be used to quantify drug release from 
monolithic dispersions with slab geometry [154,155]:
?? ? ??????????? ? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
where Mt signifies the cumulative amount of drug released at time t, A is the total surface 
area of the film exposed to the release medium, D is the diffusion coefficient of the drug 
within the matrix system, cs drug solubility in the wetted matrix  and cini the initial drug 
concentration in the matrix system. However, there are several conditions that have to be 
taken into account when the Higuchi equation is used to approximate drug release 
[151,156]: 
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? Water penetration into the slab as well as drug transport in release medium are fast, 
however the drug transport within the slab is rate limiting. 
? Dissolution of unsolved drug particles inside the slab is fast in comparison to the 
diffusion of dissolved molecules within the system. 
? Sink conditions are maintained in the receiving bulk solution throughout the 
release experiment. 
? The size of drug particles is smaller than the slab thickness and the drug is 
homogenously distributed in the matrix. 
? The diffusion coefficient remains constant. 
? The slab does not exhibit swelling or dissolve, and the surface area of the slab is 
high compared to the thickness. 
2.5 Oral mucoadhesive drug delivery systems 
The oral route is the most popular drug administration route with the highest patient 
compliance. An alternative administration route with ease of administration and high 
patient compliance is by diffusion into and through oral mucosae located in the oral 
cavity. Sublingual and buccal mucosae have been studied most extensively and there are 
currently several formulation types, such as buccal tablets, films, and sublingual tablets, 
on the market that utilize mucoadhesion for local drug administration into the oral cavity 
or through the sublingual mucosa [157]. Buccal formulations have been developed for 
example for the prevention of migraine [158] and for the local antibiotic treatment of 
periodontal diseases [159]. Advantages of mucoadhesive drug delivery include [160,161]:
(a) extending the residence time of drug compounds and localizing the effect at the target 
site, (b) high absorption rate induced by blood supply and good blood flow rates (sink 
conditions for absorption), (c) higher bioavailability through avoidance of first-pass 
metabolism, (d) less drug degradation as acidic conditions in gastrointestinal tract are 
avoided and (e) rapid onset of action.    
The oral mucosa is covered with a visco-elastic layer of mucus which constitutes mainly 
of mucins that are high molecular weight glycoproteins with a negative net charge close to 
neutral pH of oral cavity [162-164]. Absorption of mucins results in well hydrated mucus 
layers on top of epithelial cells. The role of mucin on mucosal membranes varies from 
lubricants to defensive components in the mucus layer protecting against pathogens [165].
Furthermore, mucin also functions as a biochemical filter that can bind nutrients as well as 
a wide variety of different compounds [166]. These high binding capabilities of mucins 
have been exploited in the design of bioadhesive applications in pharmaceutical and 
biomedical sciences. Mucoadhesion is defined as the attachment of formulation to the 
biological membrane; however several different mechanisms occur at the formulation-
mucus interface [167]. The mucoadhesion process involves two steps where first a close 
contact with the bioadhesive and mucus membrane is achieved and the bioadhesive 
material is wetted or swells due to the contact. Secondly, the bioadhesive material 
penetrates into the surface of the mucus membrane. Processes involved in mucoadhesion,
in addition to wetting and surface penetration, include electronic interlocking between 
negatively charged mucus membrane and positively charged polymers [168], diffusion of 
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mucoadhesive polymer chains into the glycoprotein network of the mucus layer [169] and 
adsorption due to hydrogen bonding and van der Waals forces [170].  
Polymers, both natural and synthetic, are typically used as mucoadhesive materials in 
buccal films and tablets for the encapsulation and incorporation of drugs into the mucosal 
membrane. The most important characteristics required from mucoadhesive formulations 
include sufficient swelling and wetting capabilities, hydrogen-bonding functional groups 
and flexibility to accommodate polymer network entanglement [162]. Other important 
factors are low irritation to mucosa tissue, non-toxicity, biocompatibility and 
biodegrability [171]. Typical natural polymers used are chitosan [172,173], pectin [174] 
and mucin [163,175]. They all offer high mucoadhesive properties with low toxicity. An 
example of a synthetic class polymers, poly(acrylic acid), cellulose ester derivatives, and 
polymethacrylate derivatives are the most commonly used [162]. 
Key aspects that are studied in vitro in the development of mucoadhesive film 
formulations include tensile strength, thickness, swelling, dissolution rate, and 
mucoadhesion strength [161]. Generally, buccal films should be small and flexible in 
order to be non-irritant and acceptable to patients. The swelling should be moderate to 
facilitate drug dissolution and absorption while keeping the formulation attached. The 
toxicity and irritability of the formulation should also be assessed with suitable in vitro
models prior to in vivo testing. TR146 cell-line has been utilized as a model of the human 
buccal epithelium in predicting permeability through the human buccal mucosa and 
toxicity [176,177].
The mucoadhesiveness strength of a formulation is a key parameter for ensuring the 
prolonged contact time of a formulation at the target site, which is essential for the success 
of drug therapy. Texture analysis techniques have been widely used in the evaluation of
mucoadhesive properties in vitro, such as mucoadhesiveness strength [178,179]. Various 
formulations such as hydrogels, tablets and films have been investigated with mucin disks 
and porcine buccal mucosa tissue as binding substrates. Texture analysis methods measure 
the adhesiveness between the binding substrate and the formulation. Typical outputs for 
these measurements are peak force adhesiveness and work of adhesion. Further in vivo
evaluation contains usually a buccal absorption test, perfusion study, residence time and 
pharmacokinetic study [161]. The in vitro tools offer a feasible option for formulation 
development and optimization prior to in vivo testing.  
In the experimental part of this thesis, bioadhesive NFC/ANFC films were prepared by 
incorporating natural origin biopolymers into the films. The potential of these films as 
mucoadhesive drug delivery systems for the local delivery of drugs into the oral mucosal 
tissue was evaluated in vitro. 
2.6 Freeze-drying of pharmaceuticals  
Freeze-drying (or lyophilization) is a commonly used method for drying of heat sensitive 
materials such as protein pharmaceuticals and biological samples [180-182]. The freeze-
drying process consists of three subsequent process steps of freezing, primary drying and 
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secondary drying. The low temperatures during the process protect the active materials. 
Freeze-dryers consist of chamber, condenser, vacuum pump and cooling components 
[183]. Various parameters that have an impact on the freeze-drying include the product 
(formulation, solid content), type of container (geometry, fill volume, heat transfer), 
equipment (freeze-dryer model, probes) and process (shelf/chamber temperature, chamber 
pressure, time) [182,184,185]. The following chapter will give an overview of the freeze-
drying process parameters as well as formulation aspects. Only the freeze-drying of 
aqueous solutions is considered, although it is possible to use other solvents as well for 
materials that do not dissolve in water. 
The first step in the freeze-drying process is to freeze the material in suitable vials. As the 
formulation contains essentially solutes in an aqueous solvent the resulting solution has a 
lower freezing point than the pure solvent or solute [186]. The term freezing-point 
depression is used to describe this phenomenon. The freezing rate of the material affects 
the nucleation of ice and the formation of ice crystals [187,188]. At high cooling rates 
(above 5°C/min) a large amount of small ice crystals is quickly formed, but the ice 
sublimation time is long [189,190]. Slow cooling rates (1-5°C/min) result in slower 
formation of fewer large ice crystals resulting in shorter ice sublimation time. The ice 
growth affects the texture and porosity of the final product [191]. Fast cooling rate can be 
obtained with liquid-nitrogen dipping and it has been shown to be a more suitable freezing 
method e.g. for the preservation of nanoparticle structures during freeze-drying as opposed 
to slow freezing rate [192]. Depending on the freeze dryer model, the freezing step may be 
performed prior to moving the material inside the freeze-dryer chamber, but in shelve 
temperature controlled models the freezing rate is adjusted by adjusting the temperature of 
the shelves.  
After freezing, the pressure inside the freeze-drying chamber is reduced below the 
conditions at the triple point of water (where water exists as solid, liquid and gas 
simultaneously) [193]. Lowered temperature and pressure allows the vacuum sublimation 
of solid frozen ice crystals directly from solid phase to gas phase. The vapor pressure of 
ice provides the driving force for water removal in lowered temperature and pressure 
[194]. The sublimation of ice crystals is called the primary drying cycle. Approximately 
95% of water is removed during primary drying [195]. The sublimation process usually 
moves as a “sublimation front” from the outermost exposed parts into the deeper layers of 
a sample, therefore the water vapor needs to move through the freeze-dried sample [196].
Vial fill volume (height of liquid statue) and dimensions as well as the solid content in the 
formulation create resistance to sublimation and affect the duration of primary drying.  
After primary drying the secondary drying is performed to remove any unfrozen water 
ionically-bound or adsorbed to the freeze concentrated material [197,198]. The 
temperature is typically raised higher than during primary drying to break the bonds 
between the material and remaining water molecules. The freeze-drying cycle is complete 
after the secondary drying. Normal atmospheric pressure can be restored with an inert gas 
and the vials stoppered inside the drying chamber under sterile conditions. Freeze dried 
materials have porous structure with typically low residual moisture content of 1-5 % 
[189]. 
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The stability of the active material during freeze-drying and storage as well as the total 
duration of the process are the main concerns for optimization of the freeze-drying 
process. From a formulation perspective the critical properties include eutectic melting 
temperature (Te), amorphous collapse temperature (Tc), glass transition temperature of 
maximally freeze-concentrated solution (Tg’), properties of the excipients and the stability 
of the drug itself [180]. An optimized freeze-drying process operates near the maximum 
allowable product temperature. During primary drying, the temperature should be kept 
below Te for a crystalline eutectic system and below Tc as well as Tg’ for an amorphous 
system [199]. For mixed systems that contain both crystalline and amorphous material 
lower than critical temperatures should be used (i.e. below Te, Tc, Tg’). Otherwise, the 
eutectic crystalline solid melts down or the viscosity of the amorphous solute phase 
decreases resulting in the loss of macroscopic structure, collapse of the structure and high 
residual moisture content [199,200]. Tc is typically from ca. 2°C to several degrees higher 
than Tg’ depending on the ice sublimation rate [201]. The critical temperatures of any 
formulation can be analyzed with freeze-drying microscopy or thermal analysis prior to 
freeze-drying to avoid quality issues [202,203]. The final product should have a porous 
structure with good dehydration properties and acceptable appearance. 
The main reason for freeze-drying of drugs and protein pharmaceuticals is to improve 
their storage stability [204]. Drugs, peptides, proteins and other complex molecules may 
undergo chemical reactions such as hydrolysis, crosslinking, oxidation, aggregation and 
disulfide rearrangements in aqueous solutions that affect the product stability and efficacy 
[205-207]. In the dry state these reactions can be substantially retarded thus improving 
stability during storage [208,209]. Typically excipients are added to create physical 
stability as the active material is present at low concentration in the formulation and may 
require support against dehydration stress [185,204,210]. Several, cryo- and lyoprotectants 
can be selected to increase the physical stability of proteins during-freeze-drying 
[211,212]. Generally cryoprotectants protect against protein denaturation in the freezing 
step and lyoprotectants prevent protein inactivation due to dehydration stress during 
drying [213]. Polyols such as mannitol [214,215] and disaccharides such as trehalose 
[216,217]  and sucrose [218-220] and polyhydric alcohols such as polyethylene glycols 
(PEGs) [221-223] are among the most commonly used protectants. Table 2 summarizes 
some of the most widely used cryo- and lyoprotectants used as stabilizing excipients in the 
freeze-drying of proteins.  
Table 2. Cryo- and lyoprotectants used in the freeze-drying of proteins.
Group Compound References
Polyols Mannitol, sorbitol, glycerol [224,225]
Disaccharides Sucrose, trehalose, lactose,melibiose, glucose [216,218,219,226,227]
Polymers Bovine serum albumin, dextran,PVA, PEGs, HPMC [219,226,228-231]
Non-aqueous solvents Dimethylsulphoxide, PEGs,
glycerol [221-223,232,233]
Surfactants Tween 80, Brij 35 [231,234]
Amino acids Glycine, proline [222,235]
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Freeze-drying process has been utilized for the production of highly porous NFC and 
ANFC aerogel structures [78,83]. These aerogel matrices can be used as templates for 
encapsulation and controlled release of pharmaceuticals [106]. However, rehydration of 
the aerogels back into hydrogel form has not been extensively studied due to the tendency 
of NFC/ANFC fibers to aggregate during drying. However, the carboxyl groups present 
on the ANFC fiber surface improve the rehydration of the material after drying and 
reverse the hornification to some extent [81]. In principle, cryo- and lyoprotectants could 
be used as stabilizing excipients to preserve the nano-scale structures of NFC and ANFC 
fibers during freeze-drying as there is already abundant evidence in the literature showing 
that cryo- and lyoprotectants have been used to preserve the structure and activity of 
therapeutic proteins during freeze-drying (Table 2). The structural loss of NFC and ANFC 
fiber dimensions during drying is caused by the hornification process where adjacent 
fibers aggregate together when hydrogen bonds with water molecules are lost [7]. As 
shown with proteins, cryo- and lyoprotectants can be used to replace the lost hydrogen 
bonds with water [236,237]. The fiber hornification somewhat limits the use of 
NFC/ANFC aerogels solely into the dry form as upon reconstruction back into the 
hydrogel form the rheological properties may be lost especially for NFC [79,238]. 
Consequently, there is a need to explore new materials and material combinations suitable 
for providing protection to the NFC and ANFC nano-scale structures during freeze-drying. 
As a part of this thesis, the freeze-drying and consequent rehydration of ANFC hydrogels 
in the presence of commonly used cryo- and lyoprotectants (trehalose and PEG 6000) was 
explored. More specifically, the rheological and drug release properties were evaluated 
after reconstruction of ANFC aerogels back into hydrogels. As such, the freeze-drying 
could provide opportunities for the long term storage of therapeutics encapsulated in 
cellulose fiber aerogels. Furthermore, successful rehydration could expand the use of these 
cellulose based aerogels into hydrogel dosage form that can be stored in the dry aerogel 
state and administered upon need as rehydrated hydrogels. 
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3 Aims of the study 
The aim of this thesis project was to evaluate natural cellulose based polymers for the 
encapsulation of active materials in several pharmaceutical formulation types. 
Nanofibrillated cellulose (NFC), anionic type nanofibrillated cellulose (ANFC) and novel 
microcrystalline cellulose (MCC) grades were used in the preparation of emulsions, 
hydrogels, aerogels, films and dispersions.
The specific aims of the present study were:
1. To test the suitability of NFC, ANFC and MCC for the encapsulation and 
controlled release of active materials (I, II, IV). For this purpose emulsions, 
hydrogels, aerogels and dispersions were prepared and the performance with 
regard to drug release properties was evaluated.
2. To utilize the functionality of cellulose based materials (NFC, ANFC and MCC) 
without further chemical modification. Properties of cellulose-based materials 
were exploited for drug release applications, e.g. as release rate controlling 
matrices and to prolong the contact time at drug absorption target site (III, IV).
3. To promote the use of NFC and ANFC in various drug release and therapeutic 
applications. As a stabilization agent, mucoadhesive film forming material and as a 
hydrogel and aerogel matrix for modified drug release applications (I-III).
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4 Experimental  
Complete details of all the materials, methods and equipment used in this thesis work can 
be found in the respective original publications (I-IV). 
4.1 Materials  
4.1.1 Nanofibrillar cellulose (I-III) 
1.73% NFC (GrowDex®) and 0.56 % oxidized ANFC (-COOH 1.02 mmol/g pulp) 
nanofibrillated cellulose hydrogels were kindly provided by UPM-Kymmene Corporation, 
Finland (I). Due to birch-based raw material, the NFC contained some soluble 
hemicelluloses. NFC hydrogel was diluted with ultrapure water to form 5 mg/ml stock 
solution and ANFC at 5.6 mg/ml was used as received (I). 3.2 % and 6.8 % ANFC (-
COOH 1,06 mmol/g pulp) hydrogels (FibDex™) were kindly provided by UPM-
Kymmene Corporation, Finland (II). The diameter of most of the fibrils was in the range 
of 4–10 nm with length of 500 – 10 000 nm (II). 1.5% NFC (GrowDex®) and 2.7 % 
ANFC (-COOH 1.03 mmol/g of fibers) hydrogels were purchased from UPM-Kymmene 
Corporation, Finland and used as film forming polymers (III).
4.1.2 Microcrystalline cellulose (IV) 
Three un-dried microcrystalline cellulose grades (AaltoCell™ ) termed as non-dispersed 
MCC, mechanically dispersed MCC-D and lignin containing mechanically dispersed  
MCC-L were prepared according to an earlier protocol by Vanhatalo et al. [123]. These 
were used as 2.4 %, 5 %, 10 % and 12 % (wt) gels (IV).  
4.1.3 Biopolymers: HFBII, pectin, mucin, chitosan (I, III)  
Hydrophobin class II protein HFBII from Trichoderma reesei was provided as lyophilized 
powder by VTT Technical Research Centre of Finland, Finland and used as a 5 mg/ml 
stock solution for the preparation of emulsions (I). Mucin from bovine submaxillary gland 
(EMD Millipore, USA), chitosan oligosaccharide lactate (Sigma-Aldrich, USA) and 
pectin from apple (Sigma-Aldrich, China) were used as mucoadhesive polymers in NFC 
and ANFC films (III). 
Microcrystalline cellulose (MCC, Avicel PH200, FMC BioPolymer, Ireland) and mucin 
from porcine stomach (Type-II) (Sigma-Adrich, USA) were used to prepare 600 mg 
mucin tablets (4:1 mass ratio) used as binding substrates in the evaluation of 
mucoadhesive strength (III). Tablets were wetted with 1 % solution of mucin from bovine 
submaxillary glands (Type-I) (Sigma-Aldrich, USA) prior to adhesion testing. 
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4.1.4 Model compounds and reagents (I-IV) 
Naproxen (NAP, Sigma-Aldrich, USA) and ibuprofen (IBU, Sigma-Aldrich China) were 
prepared as 1 mg/ml stock solutions in soybean oil (Sigma-Aldrich, USA) (I). The 
solubility of NAP and IBU in soybean oil and ethyl oleate was experimentally determined 
after equilibrating excess amounts of drugs for 72 h at 25 °C. 4 kDa FITC-dextran (FITC-
DEX, Sigma-Aldrich, Sweden, II), metronidazole (MZ, Sigma-Aldrich, China, II, III, 
IV), nadolol (NAD, Sigma-Aldrich, Finland, II), ketoprofen (KETO, Orion Pharma, 
Finland, II), lysozyme from hen egg (LZ, Roche, Germany, II, IV) were obtained from 
various suppliers. The most important physicochemical properties of model compounds 
are given in Table 3. 
Table 3. Physicochemical properties of model compounds.
Compound MW (g/mol) Solubility (mg/ml) pKa/pI Charge at pH 7.0 Ref.
NAP 230.3 0.0159 (MQ)2.8 - 3.6 (pH 7.4) 4.15 - [239,240]
IBU 206.3 0.021 (MQ)6 (pH 7.4) 4.85 - [241-243]
KETO 254 0.107 (25 °C),~ 40.7 (pH 7) 4.06 - [244-247]
NAD 309 8.3 (25 °C),8.3 (pH 7) 9.28 + [246,248]
MZ 171 10.5 (25 °C),10.5 (pH 7) 2.38 ø
[246,249,
250]
BSA 6.65x104 40 4.6 - 4.8 - [251,252]
LZ 1.47x104 >10 11.1 + [253,254]
FITC-DEX 4000 50 ø [252]
Soybean oil (Sigma-Aldrich, USA) and ethyl oleate (Sigma-Aldrich, UK) were used as oil 
phases in emulsions (I). Polyethylene glycol 6000 (Fluka, Switzerland) D-(+)-trehalose 
dihydrate (tre, Sigma-Aldrich, USA) were used as freeze-drying excipients (II). Sodium 
phosphate salts (Sigma-Aldrich, Germany) were used in the preparation of 0.1 M pH 7.4 
phosphate buffer (I) and 50 mM pH 6.8 phosphate buffer (III). Dulbecco’s Phosphate 
Buffered Saline (10X) concentrate without calcium and magnesium (Gibco, UK) was used 
as pH 7.4 drug release buffer (II, IV). Bio-Rad Protein Assay reagent (Bio-Rad, USA) 
was used for LZ assay (II). Acetonitrile (ACN) was of analytical grade (Sigma-Aldrich, 
Germany) (I-III). All model compounds and reagents were of analytical grade. All other 
chemical were at least of analytical grade. Ultrapure water was used to prepare all the 
solutions.  
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4.2 Production techniques  
4.2.1 Emulsification (I)  
Oil-in-water (o/w) emulsions with a 1 ml final volume and 10% oil phase were prepared 
from combinations of ultrapure water, soybean oil, ethyl oleate, HFBII, NFC and ANFC 
stock solutions. For IBU and NAP emulsions, the stock solutions of drugs in soybean oil 
were used in combination with the other formulation components. All formulations were 
premixed by repeated pipetting in Eppendorf tubes prior to ultrasound- sonication with a 
high intensity ultrasound processor (Sonics, USA) equipped with a 2 mm stepped 
microprobe (power 750 W, frequency 20 kHz and amplitude 30%). The samples were kept 
in an ice bath during 4 x 30 s of sonication and afterwards the samples were homogenized 
further in an ultrasonic bath for 1 h.  
4.2.2 ANFC hydrogel formulations (II) 
3 % and 6.5 % ANFC hydrogel formulations with 2 % MZ, 1.7 % NAD, 3.4 % KETO, 1 
% FITC-DEX, 1 % BSA and 0.5 % LZ were prepared in 10 ml syringes (II). The 
hydrogels were homogenized with the model compounds by mixing inside two attached 
syringes (200 times through the syringe nozzle). For MZ, NAD and KETO an excess 
amount of the drug in relation to solubility (at pH 7) was mixed with the ANFC hydrogels 
resulting in monolithic dispersions. For FITC-DEX, BSA and LZ the solubility limit (at 
pH 7) was not exceeded thus resulting in monolithic solutions in ANFC hydrogels. The 3 
% and 6.5 % ANFC hydrogel formulations with MZ, NAD, KETO and BSA were also 
prepared with 1 % of PEG6000 and 0.3 % of trehalose. 
4.2.3 Freeze-drying (II) 
Pure ANFC hydrogels, ANFC hydrogels with 1% of PEG6000 and 0.3 % of trehalose and 
ANFC hydrogels with MZ, NAD, KETO, BSA with 1 % of PEG6000 and 0.3 % of 
trehalose were used for the production of aerogels with a freeze-drying process (II). 2.5 ml 
of each hydrogel type was placed inside a 10 ml syringe, followed by fast liquid nitrogen 
freezing for 1 min. The frozen samples were immediately transferred to a freeze dryer 
(FreeZone 2.5, LabConco, USA) and freeze-dried in a vacuum (70 mTorr) at a 
sublimating temperature of -52 °C for 29 h. The freeze-dried aerogels were rehydrated 
gravimetrically with ultrapure water into their original concentrations. Homogenization 
inside two syringes was used to redisperse the aerogels back into their hydrogel forms. 
4.2.4 Film production by liquid molding (III) 
NFC or ANFC hydrogels were thoroughly mixed with the powders of mucoadhesive 
polymers pectin, mucin or chitosan in 10:1, 2:1 and 1:1 (NFC/ANFC: polymer) mass 
ratios relative to the dry NFC/ANFC fiber contents in 20 ml glass vials. For mucoadhesive 
strength measurements without MZ, 4 g of the hydrogel formulations (all mass ratios with 
each polymer) in plastic petri dishes (4 cm diameter) were dried for 18 h at 45 °C in an 
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oven. Films for swelling, tensile strength, solid state characterization, drug release and 
toxicity studies were prepared from 9.0 g of the hydrogel formulations placed in a 3D 
printed (Ultimaker 2+ 3D printer, Netherlands) round PLA mold (4 cm diameter) attached 
with Teflon bottom and oven dried for 18 h at 45 °C. For these measurements only films 
with 2:1 mass ratio of NFC/ANFC to either pectin or mucin were evaluated. MZ amount 
was set to 10% of cellulose and polymer dry mass in drug containing films. Films were 
prepared without MZ for tensile strength measurements, whereas for swelling, drug 
release studies, SEM imaging, solid state characterization and toxicity studies, MZ 
containing films were also used. NFC/ANFC-mucin films retained the diameter of 4 cm 
during drying, whereas for pectin films the diameter was reduced to 3.5 cm after drying. 
The films were stored inside a silica desiccator at 25 °C until used.  
4.2.5 MCC matrices (IV)
MCC (AaltoCell™) was prepared from undried pulp according to a previously described 
method [123]. The preparation of the MCC formulations with 1% of model compounds, 
MZ and LZ, was carried out by mixing the compounds as powders to the 12% MCC,
MCC-D and MCC-L dispersions. A manual mixing procedure was carried out by pressing 
the sample several times through the nozzle of two attached syringes. For MZ and LZ the 
solubility limit was not exceeded thus resulting in monolithic solutions in MCC, MCC-D
and MCC-L dispersions. 
4.3 Characterization of formulations  
4.3.1 Emulsion characterization (I)  
The zeta-potential values of emulsion droplets were measured by a ZetaSizer Nano-ZS 
(Malvern Ltd., UK) in water at 25°C in a folded capillary cell (Malvern Ltd., UK). 
Hydrodynamic diameter and size distribution of emulsion droplets were measured by 
dynamic light scattering (DLS) measurements by a ZetaSizer Nano-ZS (Malvern Ltd., 
UK) in water at 25°C in disposable polystyrene cuvettes (Sarstedt, Germany). DLS 
measurements were performed at day 1 and at day 28 after the emulsion preparation, 
whereas zeta-potential measurements were performed only at day 1. The stability of the 
emulsions during 1 month storage in glass vials at 4°C was evaluated by following the 
phase separation with qualitative emulsion stability index (ESI) values. Digital camera 
images were taken to follow the phase separation of emulsions, namely the separation of 
the clear aqueous phase from the volume fraction of opaque emulsion phase. The digital 
camera images were analyzed with ImageJ software (National Institutes of Health,
Bethesda, USA). ESI values were calculated from the volume of separated water and total 
volume as follows (5): 
??? ? ? ????????????????????                                                                                                       (5) 
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where ESI value 1 corresponds to completely unseparated emulsion whereas 0 is a value 
for completely separated system. Optical microscopy images of emulsions were taken as a 
quality control with an optical microscope (Leica DMLB, Germany) and a microscope 
coupled digital camera. The morphologies of emulsions were further imaged and 
characterized with 200 kV Tecnai F20 Cryo-TEM microscope (FEI Company, Holland). 
4.3.2 Rheology (I-II, IV)  
Dilute NFC and ANFC solutions (I): 
The shear viscosities of ultrapure water, 0.1 % and 0.15 % NFC and ANFC solutions were 
measured at 4°C with HAAKE Viscotester iQ Rheometer (Thermo Fisher Scientific, 
Karlsruhe, Germany) equipped with a Peltier system for temperature control. Cup and 
double-gap cylinder geometry was used with a 4.0 mm gap and 2.64 ml sample volume. 
Before each measurement (n=3), the samples were allowed to rest for 2 min at 4°C after 
which the measurements were performed by increasing the shear rate from 100 to 1900 
1/s.  
ANFC hydrogels (II): 
The rheological measurements were performed a with HAAKE Viscotester iQ Rheometer 
(Thermo Fisher Scientific, Germany) at 37°C equipped with a Peltier system for 
temperature control. Parallel 35 mm diameter steel plate-and-plate geometry was used 
with a 1 mm gap in all measurements. The samples were allowed to rest for 5 min at 37°C 
prior to measurements. Shear viscosity was measured by increasing the shear rate from 0.1 
to 1000 1/s. The linear viscoelastic region was determined with controlled stress amplitude 
sweeps with constant angular frequency ω = 1 Hz and oscillatory stress between 1x10-4 –
500 Pa. In the measurements for storage (G') and loss modulus (G'') the chosen oscillatory 
stresses for frequency sweeps were τ = 50 Pa (3% ANFC) and τ = 100 Pa (6.5% ANFC) 
and the angular frequency range was 0.6 - 125.7 rads-1. 
MCC matrices (IV): 
The rheological properties (n=3) of the different MCC grades were studied at 22 ˚C by 
oscillatory shear rheometer (AR-G2 Magnetic Bearing Rheometer, TA Instruments) with a
parallel 20 mm diameter steel plate geometry and 1000 μm gap. The rheological 
properties of the different MCC grades were investigated by oscillatory stress sweep and 
viscosity test. In the oscillatory stress sweep, the storage (G’) and loss (G’’) modulus were 
measured at a constant angular frequency of 1 Hz and oscillatory stress between 0.01 –
100 Pa. Shear viscosities were measured as a function of the shear rate ranging from 0.01 
to 1000 s -1. Commercial Avicel® PH-101 (Merck, Germany), was used as a reference 
material in the rheology experiments.
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4.3.3 Tensile strength (III) 
Film sample sizes were 20 x 2 mm, length and width respectively, and the films were 
equilibrated at 50 % relative humidity and stored at 20 ˚C overnight before the tensile test . 
The film samples were displaced on a measuring table with a support for displacement 
sensor (215−514 comparator stand, Mitutoyo, Japan) and film thicknesses (n=3) were 
measured by the displacement sensor (LGF-0110L-B, Mitutoyo, Japan) with a digital 
reader (EH-10P, Mitutoyo, Japan). After which, tensile test (n=3) were performed with the 
tensile tester (100 N load cell, Kammrath & Weiss GmbH, Germany) in 
Tensile/Compression Module 5 kN in a humidity controlled chamber. Average of strain-
stress curves were obtained by dividing the tensile load curve with the cross-sectional area 
of the respective sample and were used to calculate the Young’s modulus (YM), tensile 
strength, elongation and toughness.  
4.3.4 Film swelling (III) 
Film samples (n=3) of NFC/ANFC in combination with pectin or mucin (in 2:1 mass 
ratio) with approximately 1 cm2 surface area were immersed into 50 mM pH 6.8 phosphate 
buffer for 15 s or 5 h at 25 °C. The film weight was measured prior to and after the 
hydration period in the buffer and also after re-drying for 20 h at 45 °C. The weight 
increase as hydration percentage (n=3) was calculated with the following equation: 
Hydration % = (Xt – X0) / X0 x 100           (6)
where Xt is the weight of the swollen sample and X0 is the original weight of the sample. 
The mass of the original sample was compared to the corresponding weight after the 
swelling test and re-drying to obtain mass loss percentage (n=3) as follows: 
Mass loss % = (X0 – Xd)/X0 x 100                                 (7) 
where Xd is the weight of the re-dried sample. The effect of swelling on surface area after 
30 min exposure to the release buffer was evaluated only for selected formulations used in 
the drug release studies. The original dry film thickness was obtained from SEM images 
(n = 10), whereas surface area in dry and wetted state, as well as thickness in the wetted 
state were obtained from digital camera images with ImageJ software (National Institutes 
of Health, Bethesda, USA). 
4.3.5 Mucoadhesive strength (III)  
Mucoadhesive strength of the NFC/ANFC films combined with pectin/mucin/chitosan 
was evaluated with a texture analyzer TA.XT plus (5 kg load cell, Stable Microsystems 
Ltd, UK) in texture profile analysis (TPA) mode. 13 mm diameter mucin-MCC tablets 
were direct compressed (force 3000 kg, 30 s) in a Carver press and the tablets were 
attached horizontally into the lower end of a 10 mm diameter TA.XT plus probe and the 
whole tablet surface was wetted with 1 % mucin solution. Each film type (n=3) was
placed under the analytical probe in flat Petri dishes and the probe was lowered until the 
mucin disc was in close contact with the surface of the sample. Parameters used in the 
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measurements included: 0.50 mm/s pre-test speed, 0.30 mm/s test speed, 0.3 mm/s post-
test speed, 100 g applied force, 4 mm return distance, 15 s contact time and 3 g trigger 
force. Exponent software (Stable Microsystems Ltd., UK) was used is results analysis and 
peak adhesion force (N) required to detach the mucin tablet from the surface of the film 
was used as the measure of mucoadhesive strength. 
4.3.6 Solid state analysis (II-III) 
ANFC aerogels (II): 
The morphology of the freeze-dried aerogels was evaluated from cross-section and surface 
structure micrographs obtained with a scanning electron microscope Quanta FEG250 
(SEM, FEI Company, USA). Aerogel samples fixed onto a two-sided carbon tape were 
sputtered with platinum for 25s with an Agar sputter device (Agar Scientific Ltd., UK) 
prior to imaging. The residual moisture content of the aerogels was determined by heating 
the samples from 25 to 240°C at a heating rate of 10°C/min in nitrogen (40 ml/min) 
atmosphere using a TGA (TGA 850, Mettler-Toledo, Switzerland). Mass loss (%) of 
evaporated water was used to quantify the residual moisture content of the aerogels.
Thermal analyses of ANFC aerogels were carried out using a differential scanning 
calorimeter Mettler Toledo DSC 823e (Mettler Toledo, Giessen, Germany). The samples 
were placed in sealed aluminum pans with closed lids and heated at a scanning rate of 10 
°C/min between 25 and 200 °C in nitrogen atmosphere. 
Bioadhesive NFC and ANFC films (III): 
The morphology of the films was evaluated from cross-section and surface structure 
micrographs obtained with a scanning electron microscope (SEM, FEI Company, USA). 
Prior to imaging, the samples fixed onto a two-sided carbon tape were sputtered with 
platinum for 25s with an Agar sputter device (Agar Scientific Ltd., UK). Thermal analysis 
of selected films was carried out by heating the samples at a scanning rate of 10 °C/min 
between 25 and 220 °C in nitrogen atmosphere using a differential scanning calorimeter 
Mettler Toledo DSC 823e (Mettler Toledo, Giessen, Germany). ATR-FTIR spectroscopy 
was carried out to characterize the films, using a Vertex 70 FTIR spectrometer (Bruker 
Optik GmbH, Germany) with a MIRacleTM single reflection ATR crystal (Pike 
Technologies, Inc., USA). The analytical range in the measurements was 650 to 4000 cm-1
with a spectral resolution of 4 cm-1. Principle component analysis (PCA) was used to 
evaluate the data, and it was performed with standard normal variate (SNV) transformed 
and mean-centered spectra using SIMCA software (Sartorius Stedim Biotech, Sweden). 
Raman spectroscopy analysis was performed for the films with a Raman RXN1 
spectrometer, equipped with a PhAt probe head and a 20-mW laser source operating at 
785 nm (Kaiser Optical systems, Inc., USA). The spectra were analyzed after removal of 
elevated baselines using a rubberband correction method (Opus software, Bruker Optik 
GmbH, Germany). The spectra were normalized by SNV transformation and mean 
centering before analysis by PCA (SIMCA software, Sartorius Stedim Biotech, Sweden). 
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4.3.7 Dissolution studies (I-IV)
Emulsions (I): 
In order to determine the drug release characteristics of NAP and IBU from emulsions the 
side-by-side-diffusion cells (Laborexin, Finland) were used. Nuclepore Track-Etch 
polycarbonate membrane filters (0.4 μm pore size, surface area of 0.785 cm2) were 
clamped between two identical halves of diffusion cells. 0.8 ml of drug containing 
emulsion (0.1 mg/ml of drug) was transferred into the donor compartment (n=3). Donor 
and acceptor compartments were filled to 3.5 ml final volume with buffer solution (0.1 M 
phosphate pH 7.4). The diffusion cells were kept at 37°C by a surrounding water socket to 
mimic physiological conditions. The control samples in the donor compartment contained 
free drug solutions of NAP and IBU at 0.08 mg drug / 3.5 ml volume corresponding to 
100 % of drug in the emulsions. Samples were collected from the acceptor compartment 
up to 8 h and replaced with fresh buffer. 
ANFC hydrogels (II) and MCC matrices (IV): 
1.07 g of ANFC hydrogel formulations were used to fill disc molds with a constant flat 
surface area of 1.33 cm2 exposed to the release buffer (II). The discs were placed inside 
150 ml amber glass vials, which were then filled to a final volume of 70 ml with pH 7.4 
phosphate buffered saline and kept at 37°C under constant magnetic stirring (400 rpm) on 
top of a multi-position magnetic stirrer IKA RT10 (IKA-Werke GmbH & Co KG, 
Germany). Samples were withdrawn up to 144 h and replaced with fresh buffer (n=3). The 
diffusion coefficients for NAD, KETO and MZ (II) inside hydrogels (initial drug 
concentration ˃ drug solubility) with slab geometry were calculated with Higuchi equation 
(5) which was reduced to (6) as in the system Cini ˃ Cs [154-156,255]:
? ? ???????? ? ?????????           (8)                          
?
? ? ??????????           (9)
where Q is the amount of drug released in time t per unit area, D is the diffusion 
coefficient of the drug within the matrix system, Cini represents the initial drug 
concentration in the matrix system, Cs is the drug solubility in the matrix media. Diffusion 
coefficients for FITC-DEX, BSA and LZ (II) inside ANFC hydrogels (initial drug 
concentration ˂ drug solubility) with slab geometry were calculated with the unsteady-
state form of Fick’s second law of diffusion (2) with early values of time when 0 ˂ Mt/M∞
˂ 0.6 [151]: 
??
?? ?? ? ?
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where Mt and M∞ denote the cumulative amounts of drug released at time t and infinite 
time ∞; D is the diffusion coefficient of the drug within the matrix system; L represents 
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the thickness (1 cm) of the hydrogel. D was obtained from fitting the data of Mt/M∞ at 
selected time points.  
For MCC matrices, the setup for the drug release studies of MZ and LZ (IV) was similar 
to that of ANFC hydrogels, however here 1.11 g of MCC formulations were used to fill 
the disc molds and for both compounds: initial drug concentration ˂ drug solubility. The 
diffusion coefficients inside MCC matrices were calculated with the unsteady-state form 
of Fick’s second law of diffusion (2) with early values of time when 0 ˂ Mt/M∞ ˂ 0.6. D
was obtained from fitting the data of Mt/M∞ at selected time points.  
NFC and ANFC mucoadhesive films (III): 
Films were cut into squares with an area of 1 cm2 and placed inside 20 ml glass vials, 
which were filled with 10 ml of 50 mM pH 6.8 phosphate buffer. The drug release studies 
(n=3) were performed inside an incubator shaker Titramax 1000/Incubator 1000 
(Heidolph, Germany) at 37 °C (200 rpm) and samples were collected up to 30 min and 
replaced with fresh buffer. 
4.3.8 Analysis of the model compounds (I-IV) 
NAP (I), IBU (I), KETO (II), NAD (II) and MZ (III) concentrations from the drug 
release samples (I) were analyzed with Ultra performance liquid chromatography (UPLC) 
instrument Acquity UPLC (Waters, USA). UPLC parameters are summarized in Table 4. 
Table 4. UPLC parameters for quantification of the drugs.
Drug Column Mobile phase λ (nm)
NAP BEH Shield 1.7 μm(Waters, USA)
ACN:15 mM phosphate buffer pH 2
30:70 ratio 231
IBU HSS-C18 1.8 μm(Waters, USA)
ACN:15 mM phosphate buffer pH 2
60:40 ratio 219
KETO HSS-C18 1.8 μm(Waters, USA)
ACN:15 mM phosphate buffer pH 2
25:75 ratio 255
NAD HSS-T3 1.8 μm(Waters, USA)
ACN:15 mM phosphate buffer pH 2
10:90 ratio 215
MZ Primesep 100 5 μm(Waters, USA)
ACN:15 mM phosphate buffer pH 2
20:80 ratio 317
FITC-DEX quantification (II), at excitation wavelength of 490 nm and emission 
wavelength of 520 nm, was performed by fluorescence intensity measurements with 
Varioskan Flash (Thermo Fisher Scientific, Finland). MZ (II, IV) and LZ (II, IV) 
quantification at wavelengths of 320 nm and 280 nm respectively was performed by 
spectrophotometric analysis with Cary 100 UV-Vis (II) or Cary 50 UV-Vis (IV) 
spectrophotometer (Varian Inc., USA). BSA quantification (II) was performed by 
linearized colorimetric Bio-Rad protein assay, which is based on Bradford dye-binding 
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method [256,257], by measuring absorbance at 470 nm and 595 nm with Varioskan Flash 
(Thermo Fisher Scientific, Finland).
4.3.9 Toxicity studies with TR146 human buccal epithelium model (III) 
Human squamous cell carcinoma, TR146 (passage #9, Sigma-Aldrich, UK) cells were 
cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12, 
Gibco™, Thermo Fisher, USA) supplemented with 10 % Fetal Bovine Serum (FBS, 
Thermo Fisher, USA) and 2mM L-glutamine (GlutaMAX™, Thermo Fisher, USA). Cells 
were sub-cultured and incubated at 37°C, 5 % CO2, and seeded into a standard cell culture 
96-well plate for cytotoxicity studies (2x104 cells/well). Round pieces (Ø = 5 mm, n = 4) 
of bioadhesive films were cut and inserted into the wells with and without cells and 
incubated for 24 hours. After the incubation the films were removed and the cell 
proliferation reagent resazurin (alamarBlue®, Thermo Fisher, USA) was introduced into 
the wells followed by incubation and well plate measurement with Varioskan LUX 
multimode microplate reader (Thermo Fisher, USA) at excitation 565 nm and emission 
585 nm wavelengths. 
5 Results and discussion 
5.1 NFC and ANFC as emulsion stabilizers (I)  
It has been shown in our previous study that hydrophobin fusion proteins and NFC can be 
effectively used to stabilize o/w emulsions prepared from hexadecane and water solutions 
[6]. In the follow-up study presented here, the emulsions were further evaluated for: a) the 
ability of HFBII and NFC to stabilize the emulsions with pharmaceutically acceptable oils, 
b) the ability to control the drug release rate of poorly water-soluble BCS class II drugs 
naproxen (NAP) and ibuprofen (IBU) and c) the effect of the two different fiber grades, 
NFC and ANFC, on the stability and drug release. 
5.1.1 Emulsion stability optimization  
All emulsions were prepared with ultrasound sonication. The composition of the 
emulsions was 10% soybean oil/ethyl oleate and 90% water, which included the 
stabilizers. Reportedly HFBII is applicable for emulsion stabilization even at low 
concentrations due to the tendency of HFBII to adsorb on hydrophobic interfaces, 
converting them into hydrophilic and vice versa [258]. A series of HFBII stabilized 
emulsions were prepared to estimate the minimum amount of the protein required to gain 
stable emulsion droplets with the sonication method. Droplet diameters and zeta potential 
values as a function of protein concentration were measured. Higher HFBII concentrations 
above 0.5 mg/ml improved the stability, as the emulsion droplet sizes were effectively 
reduced, while the zeta potential values increased. After storage for 28 days a significant 
increase in droplet size and PDI values were observed for emulsions with low HFBII 
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content indicating insufficient stabilization. On the contrary, emulsions with HFBII 
content above 1 mg/ml had a decrease in the droplet sizes and PDI values at day 28. As 
HFBII has a tendency to self-associate and form tetramers in an aqueous solution at 0.5 - 
10 mg/ml concentration range [259] it is likely that the changes were caused by the loss of 
excess protein at the o/w interface. The diameter of HS-3 emulsion droplets ( ̴ 300 nm) was 
least susceptible to changes during storage, and therefore the 1 mg/ml (0.1 %) HFBII 
concentration was selected for further emulsion stabilization studies with NFC and ANFC. 
The ultrasound sonication process produced polydisperse size distribution for emulsion 
droplets; therefore other production techniques such as microfluidization [260] could offer 
more feasible options for the process scale-up and production of monodisperse droplets.  
The emulsion stability index (ESI) was used as a qualitative measure for phase separation 
in further emulsion stability studies. NFC or HFBII at a predetermined concentration 
range of 0.1 - 1.5 mg/ml [6] were tested as sole emulsion stabilizers (Figure 5A and 5B). 
The stability was increased in direct proportion to the stabilizer amount.   
Figure 5. Emulsion stability study up to 28 days. Emulsion stability index (ESI) values 
describe the phase separation of emulsions (ESI = 1 unseparated, ESI = 0 completely 
separated). The different emulsion formulations were: A) NFC-N/S (0.1-1.5mg/ml), B) 
HFBII/S (0.1-1.5mg/ml), C) HFBII-NFC-N (1/0.5-1.5 mg/ml)/S or E, D) HFBII-NFC-O
(1/0.5-1.5 mg/ml)/ S or E. Abbreviations: H = HFBII, CN = NFC-N (NFC), CO = NFC-O
(ANFC), S = soybean oil and E=ethyl oleate.
In the previous study [6] it was shown that a continuous NFC matrix is formed in the 
aqueous phase of o/w emulsions at approximately 1 mg/ml NFC concentration and further 
stabilization was achieved by combining NFC with hydrophobin proteins (HFBs). Similar 
results were obtained in our study as the emulsion stability was further increased when 
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adequate amount of NFC or ANFC (1 - 1.5 mg/ml) was combined with HFBII (Figure 5C
and 5D). Based on ESI values the soybean oil emulsions were more stable in comparison 
to ethyl oleate ones when adequate amounts of stabilizers were used. 
The stabilizing effect of NFC/ANFC was hypothesized to be attributed to the 
concentration dependent viscosity modification of the continuous aqueous phase with 
NFC/ANFC. This reportedly creates a polymer network that limits drop collision, thus 
reducing the coalescence phenomena [72,73,261,262]. Shear viscosities of NFC and 
ANFC were measured in order to distinguish between the differences in the ability to 
modify the viscosity of the continuous aqueous phase (Figure 6). The viscosity profile of 
NFC up to 0.15 % was similar to pure water, whereas ANFC had a moderate shear 
thinning behavior and approximately ten times higher viscosity values than NFC. Clearly, 
ANFC even at these fairly low concentrations ANFC was more effective rheology 
modifier than NFC. The stabilizing effect of NFC at low concentrations was likely 
attributed to the reduced emulsion droplet movement rather that the increased viscosity of 
the continuous phase. 
Figure 6. Shear rate viscosities of water, 
0.1 % and 0.15 % of NFC-N (NFC) and 
NFC-O (ANFC) at 4 °C (mean ± S.D., 
n=3).
In order to select the preferable oil phase for the emulsions, the solubilizing capacity of 
soybean oil and ethyl oleate was determined for model compounds NAP and IBU (Table 
5). Ethyl oleate had a higher solubilizing capacity for both drugs than soybean oil. The 
structural differences of the vegetable origin soybean oil and the fatty acid ester ethyl 
oleate attribute to the different drug solubilizing capacities of these oils [263-265].
Nevertheless, the solubility of both drugs in the oils was significantly (at least 100-fold) 
higher than the corresponding aqueous solubility in unbuffered water (MQ) ensuring 
effective solubilization in the emulsion formulations. 
Table 5. Physicochemical properties of NAP and IBU. Solubility in soybean oil and ethyl 
oleate was verified experimentally. 
Compound Molar mass 
(g/mol)
pKa logP Solubility in
aqueous media
Solubility in 
soybean oil
Solubility in
ethyl oleate
NAP 230.3 4.15 3.18 15.9 mg/L, MQ
a
2.8 - 3.6 g/L, pH=7.4b 2.8 g/L 5.1 g/L
IBU 206.3 4.85 3.97 21 mg/L, MQ
c
6 g/L, pH=7.4d,e 46.2 g/L 98.7 g/L
a [240], b [239], c [241], d [242], e [243]  
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As in the preliminary experiments, soybean oil based emulsions were more stable than 
ethyl oleate formulations; soybean oil was selected for drug containing formulations. The 
formulations contained 0.1 % (1 mg/ml) of HFBII alone or in a combination with either 
NFC or ANFC in 1:1 or 1:1.5 mass ratios to HFBII. Based on solubility screening, the 
drug amount in the emulsions could be improved simply by increasing the drug 
concentration in the oil phase or alternatively by increasing the volume of the oil phase. 
However, further studies would be required to optimize the stabilizer amounts for 
emulsions with a higher oil phase volume. 
5.1.2 Morphology and drug release 
Light microscopy and cryo-TEM was used to confirm the expected stabilization 
mechanism for emulsions selected for drug release studies: a combination of HFBII 
stabilized oil droplets within NFC/ANFC fiber network. Spherical morphology and 
polydisperse droplet size, with diameters ranging from below 100 nm to few micrometers, 
was observed (Figure 7). HFBII coated droplets were encapsulated within the NFC and 
ANFC fiber networks. Interestingly, ANFC emulsions were more stable upon dilution as a 
more uniform droplet distribution and even distribution in the fiber network was observed. 
Furthermore, the shorter ANFC fibers effectively surrounded the droplets that had a 
tendency to form clusters. Conversely, upon dilution uneven NFC network was observed 
with less uniform distribution of the emulsion droplets within the NFC matrix. 
Figure 7. Light microscopy images at 1:10 dilution (A-C) and cryo-TEM images (D-F) of 
HFBII, HFBII-NFC-N (NFC) and HFBII-NFC-O (ANFC) emulsions (1:1 mass ratio). 
Scale bar is 40 μm for A-C, 100 nm for D-E and 200 nm for F images.
The drug release profiles of both model compounds, NAP and IBU, are presented in 
Figure 8. Major differences were observed based on the NFC and ANFC fiber grade. The 
drug release from NFC formulations reached 64 - 70 % for NAP and 67 % for IBU during 
8h and resembled immediate release profiles of free drug solutions. Sustained release 
profiles were obtained with ANFC emulsions as only 18 – 27 % of NAP and 20 - 23 % of 
35
IBU was released during 8h. Surprisingly, for solely HFBII stabilized emulsions an 
immediate release profile was obtained for IBU whereas a more sustained release for NAP 
was observed. Physical interactions such as stability, viscosity and the diffusion barrier of 
the emulsion droplets were most likely the critical traits in determining the drug release 
rates. ANFC and NFC are both negatively charged at pH 7.4. However, the carboxylated 
ANFC fibers have a greater negative net charge [45,111]. It is likely that the sustained 
release profiles from ANFC formulations were attributed to a greater surface barrier on the 
emulsion droplets created at the o/w-interphase through electrostatic attraction between 
negatively charged ANFC and positively charged HFBII. For NFC the effect was not as 
pronounced, resulting in immediate drug release profiles. 
Figure 8. Drug release studies with NAP and IBU: A) cumulative release (%) of NAP 
(mean ± S.D., n=3-5) and B) cumulative release of IBU (mean ± S.D., n=4-5) from 
different formulations. Mass ratios of HFBII to NFC-N (NFC) or NFC-O (ANFC) are in 
brackets. Free drug solutions of NAP and IBU were used as controls for immediate 
release.
For solely HBFII stabilized emulsions, the solubility differences of model compounds at 
pH 7.4 were reflected in the release rates as it has been reported that the solubility of the 
diffusing species can have a greater effect on drug release rate than the interfacial film 
properties of the emulsion droplets [266]. HFBII controlled the drug release to some 
extent, but it was beneficial to add NFC / ANFC into the formulations to gain well defined 
release profiles. Chemical interactions with the drug molecules, such as aromatic π 
stacking, hydrogen bonding and electrostatic interactions were possible reasons for this 
effect [106,110,267]. Nevertheless, physical interactions were most likely more significant 
in determining the drug release rates. 
In summary, the study showed that natural biopolymers HFBII, NFC and ANFC are 
applicable for stabilization of pharmaceutical emulsions. The stabilization was achieved 
with extremely low concentrations, providing an alternative to synthetic polymers. 
Furthermore, the drug release profiles could be tuned by the choice of fiber grade. HFBII-
ANFC emulsions were effective in controlling the drug release rate, indicating the 
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suitability of these materials for controlled drug release applications. HFBII-NFC 
emulsions on the contrary, were more suitable for immediate drug release applications. 
Further studies are needed to determine the long term storage stability as well as stability 
in the gastrointestinal tract. Proteases (enzymes that perform proteolysis) present in the 
gastrointestinal tract could greatly affect the drug release properties from protein stabilized 
emulsions. 
5.2 ANFC hydrogels and reconstructed hydrogels (II)  
The potential of concentrated 3 % and 6.5 % ANFC hydrogels as controlled drug release 
matrices for several types of small (˂ 500 M) and large (˃ 1 kDa) molecular weight 
compounds was evaluated. The storage stability of pharmaceutical formulations is 
typically improved in the dry form, and therefore the hydrogels were freeze-dried and 
rehydrated back into the hydrogel form in order to evaluate the effect of the freeze-drying 
process on the performance of the hydrogels as controlled release matrices. The 
rheological and drug release properties were evaluated prior to and after freeze-drying and 
consequent rehydration to distinguish quality differences. Since cellulose-based ANFC 
fibers have a tendency to aggregate during drying, a combination of trehalose and PEG 
6000 was evaluated as a cryo- and lyoprotectant against the hornification of ANFC fibers 
in order to preserve the nano-scale structure of ANFC fibers. 
5.2.1 Aerogel characterization 
The produced ANFC aerogels did not shrink considerably during freeze-drying and had a 
clear porous structure (Figure 9). High porosity and similar morphology was observed for 
all aerogels and the addition of model compounds did not alter the morphology 
significantly. As rapid liquid nitrogen freezing produces a large number of small ice 
crystals [180], the selected fast freezing method promoted the formation of porous ANFC 
aerogel structure during freeze-drying. Furthermore, the high protonation of ANFC 
carboxyl groups aids in the formation of porous ultrathin lamellar aerogel structures and 
high water uptake upon rehydration [268]. Regardless of the rather similar morphology of 
3 % and 6.5 % ANFC aerogels, differences were observed in the rheological properties 
before and after the freeze-drying and rehydration process. The wettability and re-gelling 
of the aerogels was improved by the use of PEG 6000, which is recognized as a 
hygroscopic polymer that improves water uptake [269]. 
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Figure 9. SEM micrographs of highly porous 3 % and 6.5 % ANFC aerogels, 200 μm 
scale bar. Aerogels were freeze-dried without (left) and with the excipients (right,
abbreviation: exp = 0.3 % trehalose/1 % PEG 6000).
The residual moisture content was low in all aerogels indicating effective water 
sublimation during freeze-drying (Table 6). The small differences in residual moisture 
contents between 3 % and 6.5 % ANFC aerogels were likely attributed to the higher fiber 
content present in the 6.5 % starting material as the tightly bound surface water amount 
remained higher. The ability of trehalose to perform as a cryo-/lyoprotectant is attributed 
to its ability to replace water molecules hydrogen bonded to polar groups on the surface of 
materials during freeze-drying [236,237]. The amount of surface bound water on ANFC 
fibers was reduced due to this mechanism and lower residual moisture contents were 
observed when trehalose and PEG were used in the formulations. The hydrophilicity of 
model compounds was reflected on residual moisture contents of aerogels.  
Table 6. TGA and DSC analysis of ANFC aerogel formulations after freeze-drying (n=1). 
All formulations expect plain ANFC aerogels contained excipients. Abbreviation: exp = 
0.3 % of trehalose / 1 % of PEG 6000. 
Formulation Water content (%) Tm (?C) for drug or ANFC
ANFC 3 % 6.77 171.5
ANFC 3 % + exp 4.11 170 (ANFC/trehalose)
ANFC 6.5 % 7.48 174.0
ANFC 6.5 % + exp 5.81 187 (ANFC/trehalose)
BSA 1 % / ANFC 3 % 4.79 nd
BSA 1 % / ANFC 6.5 % 6.05 nd
MZ 100 % reference nd 159.4
MZ 2 % / ANFC 3 % 2.42 148.7
MZ 2 % / ANFC 6.5 % 4.98 143.5
NAD 100 % reference nd 128.8
NAD 1.7 % / ANFC 3 % 2.90 127.3
NAD 1.7 % / ANFC 6.5 % 4.79 128.3
KETO 100 % reference nd 94.6
KETO 3.4 % / ANFC 3 % 1.96 81
KETO 3.4 % / ANFC 6.5 % 3.84 84
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Thermal analysis with DSC showed a reduction in the onset melting points of model 
compounds with regard to pure references indicating interactions between the ANFC 
fibers and model compounds (Table 6). However, further binding studies would be 
required to confirm the binding mechanism of the drugs with the cellulose fibers.   
5.2.2 Rheological properties 
The aerogels were rehydrated and reconstructed with enhanced mechanical mixing. The 
rheological properties after reconstruction were compared to the original hydrogels. Shear 
viscosities of plain 3 % and 6.5 % ANFC hydrogels were significantly higher (ca. 150%) 
than the corresponding viscosity values of reconstructed hydrogels (Figure 10). This 
indicates the formation of aggregates in the hydrogels, since free individual fibers are 
responsible for the high viscosity of ANFC and NFC. A striking difference was seen when 
the excipients were included in the hydrogels: the viscosity values before and after-freeze 
drying were nearly overlapping. The addition of model compounds into hydrogels with 
excipients did not significantly alter the viscosity profiles (before and after freeze-drying) 
regardless of the high (i.e. undissolved) amount of small molecules (MZ, KETO and 
NAD). The shear-thinning behavior of a pseudoplastic material typical for ANFC 
hydrogels [63,65-67] was observed for all samples.  
Figure 10. Shear viscosity of plain 3 % and 6.5 % ANFC hydrogels before and after 
freeze-drying and redispersion without (a) and with (b) excipients (mean ± S.D., n=3). 
Abbreviations: FD = freeze-drying, exp = 0.3 % trehalose / 1 % PEG 6000. 
The viscoelastic properties of ANFC hydrogels prior to and after freeze-drying (with and 
without excipients) were also studied (Figure 11). The storage modulus (G’) decreased 
after freeze-drying for all samples. Nevertheless, the G’ values could be recovered 
significantly better with the use of excipients. The G’ values of reconstructed ANFC 
hydrogels containing excipients resembled the values of original plain ANFC hydrogels 
without excipients prior to freeze-drying on both concentrations (3 % and 6.5 %). 
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Figure 11. Storage (G’) and loss modulus (G’’) of ANFC hydrogels before and after 
freeze-drying and redispersion (mean ± S.D., n=3). Abbreviations: FD= freeze-drying, 
exp= 0.3 % trehalose / 1 % PEG 6000.
All samples, including hydrogels with model compounds, had higher G’ than G’’ values 
indicating an elastic behavior in ANFC hydrogels [63]. The presence of excipients 
reduced the effects of freeze-drying as at higher frequencies both G’ and G’’ reminded 
those of the original samples, indicating higher preservation of the elastic properties when 
compared to samples freeze-dried without excipients. Without excipients, the ratio of G’ 
and G’’ decreased and the viscous characteristics became more apparent over the elastic
properties [270]. Based on the rheological measurements, the excipients preserved the 
structural integrity and limited the formation of aggregates. Therefore, it was apparent that 
excipients aided in the preservation of the rheological properties of ANFC hydrogels 
during freeze-drying. 
5.2.3 Drug release and diffusivity 
Based on previous publications, pH dependent electrostatic forces were expected to be the 
main binding mechanism of cationic drugs into ANFC fibers, whereas π stacking and 
hydrogen bonding may take place for neutral and anionic drugs in addition to electrostatic 
interactions [110]. The measured release profiles are presented in Figure 12. The diffusion 
coefficients of model compounds were calculated for the evaluation of diffusion rates 
without the impact of solubility inside ANFC hydrogels (Table 7). 
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Figure 12. Cumulative release profiles of MZ, NAD, KETO, BSA, LZ and 4 kDa FITC-
DEX from ANFC hydrogels (mean ± S.D., n=3): (a) plain 3 % ANFC, (b) 3 % ANFC with 
excipients before and after freeze-drying, (c) plain 6.5 % ANFC and (d) 6.5 % ANFC with 
excipients before and after freeze-drying. Release buffer was PBS (pH 7.4) at 37°C. 
Table 7. Diffusion coefficients in different ANFC hydrogel matrices. Freeze-dried 
formulations were reconstructed prior to diffusion studies. The net charge of model 
compounds at pH 7 in parenthesis. Abbreviation: exp= 0.3 % trehalose / 1 % PEG 6000. 
Compound
Diffusion coefficients in different ANFC hydrogels (10-8 cm2/s)
3% 
ANFC
3% 
ANFC/exp
FD 3% 
ANFC/exp
6.5% 
ANFC
6.5 % 
ANFC/exp
FD 6.5% 
ANFC/exp
Ketoprofen (-) 62.9 60.9 54.5 58.0 52.8 47.4
NAD (+) 365.6 393.4 383.4 301.1 322.3 349.7
Metronidazole (ø) 745.7 823.0 841.5 733.3 761.8 779.6
BSA (-) 7.7 23.4 22.0 7.4 15.2 9.5
Lysozyme (+) 4.0 nd nd 2.3 nd nd
4 kDa FITC-
dextran (ø) 58.9 nd nd 35.6 nd nd
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The obtained release profiles were rather similar from corresponding plain and excipient 
containing hydrogels for both ANFC concentrations. Typically, small molecules have 
diffusion coefficients between 600 - 900 x 10−8 cm2/s in water [271], whereas diffusivity 
values of 104 x 10-8 x cm2/s and 60 x 10-8 cm2/s for LZ and BSA have been reported 
[272,273]. In this regard, apart from MZ, ANFC hydrogels provided significant control for 
diffusion-mediated release of both small and large compounds.  
The charge of small molecules had a weak to moderate impact on the cumulative release 
profiles from anionic ANFC matrices. Freeze-drying and rehydration had only minimal 
impact, whereas 6.5 % fiber concentration hindered the diffusion of small molecules more 
than the 3 % concentration. For the larger model compounds, net charge at pH 7, 
molecular size and ANFC fiber content all had a significant impact on the cumulative 
release profiles. Fastest release occurred in the order of 4 kDa FITC-DEX (ø) ˃ 66.5 kDa 
BSA (-) ˃ 14.7 kDa LZ (+). Therefore, the charge of the molecule could be more 
significant than the hydrodynamic diameter for large molecules (˃ 14 kDa), in terms of 
impact on the diffusivity in the ANFC matrices.  
In summary, this study demonstrated that ANFC hydrogels can be freeze-dried and 
redispersed without affecting rheological and drug release properties. The cryoprotectants 
aided in preserving the structure of ANFC fibers during the freeze-drying process as 
rheological properties remained unaltered upon rehydration. As such the aerogel form of 
ANFC can be easily hydrated and administered upon need thus benefitting from higher 
storage stability in the dry form. Furthermore, ANFC hydrogel matrices are applicable for 
controlled drug release applications of several types of molecules. 
5.3 MCC dispersions (IV)  
Novel type MCC hydrogel dispersions (AaltoCell™), manufactured from never-dried 
pulp, were evaluated for their rheological properties and further for their applicability in 
controlled drug release applications. The evaluated matrices consisted of non-dispersed 
MCC, mechanically dispersed MCC-D and mechanically dispersed lignin containing 
MCC-L. Due to their colloidal stability, similarity in their rheological properties and 
feasible manufacturing processes, the new MCC hydrogels were evaluated as potential 
matrices for similar applications as NFC/ANFC hydrogels in the field of controlled drug 
release. 
5.3.1 Morphology and rheology 
The morphology of MCC (non-dispersed) prior to mechanical homogenization (Figure 13) 
reminded the form of cellulose fibers used as the starting material in the process, and 
rather large particles were visible in addition to finer fibers and their pieces. In the close 
up images of the mechanically treated grades, MCC-D and MCC-L, the material appeared
to consist mostly of small fiber fragments and fine fibers with opened fibrillar structure.
Therefore, the mechanical treatment effectively reduced the particle size of MCC and the 
majority of the needle-like fibrillary surface cellulose crystals had dimensions below 10 
42
μm (MCC-D, MCC-L). Furthermore, the porosity of AaltoCell™ MCC grades is
reportedly high, with pores in a 27 - 216 nm diameter range [124].
Figure 13. SEM images of MCC (non-dispersed, A - B), MCC-D (mechanically dispersed, 
C - D) and MCC-L (lignin containing, E - F). Scale bar 20 μm (A, C, E) or 2μm (B, D, F). 
The rheological measurements (Figure 14, Figure 15) confirmed the gel-forming ability of 
MCC, MCC-D and MCC-L matrices. The mechanically dispersed MCC-L had the highest 
elastic modulus (~ 100kPa), followed by MCC-D (~ 10 kPa) and the non-dispersed MCC 
(~ 1 kPa). The Avicel suspension (used as a reference) had the lowest values at the Pa 
range. For MCC-D, the concentration dependent elastic moduli were confirmed between 
2.4 – 12 wt-%. In the viscosity measurements, a shear thinning behaviour with linear 
dependence between viscosity and shear rate was observed. Similarly to elastic moduli 
values, MCC-L had the highest viscosity followed by MCC-D, MCC and Avicel. The 
mechanical treatment of MCC-D and MCC-L resulted in higher viscosity as well as higher 
elasticity, thus the ability to form a gel was greater than for the non-dispersed MCC or 
commercial Avicel. Structurally the hydrogels consist of individual MCC particles in a
network, and for MCC-D and MCC-L colloidal stability was obtained via mechanical 
treatment.
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Figure 14. A) Storage modulus as a function of the oscillatory stress at 10 wt-% for MCC-
L (black up-pointing triangles), MCC-D (red squares), MCC (blue dots) and Avicel (green 
down-pointing triangles). B) Storage modulus as a function of the oscillatory stress for 
MCC-D at 12 wt-% (black up-pointing triangles), 10 wt-% (red squares), 5 wt-% (blue 
dots) and 2.4 wt-% (green down-pointing triangles). Results presented as mean ± S.D., 
n=3. 
 
Figure 15. A) Shear viscosity for 10 wt-% MCC-L (black up-pointing triangles), MCC-D 
(red squares), MCC (blue dots) and Avicel (green down-pointing triangles). B) Shear 
viscosity for MCC-D at 12 wt-% (black up-pointing triangles), 10 wt-% (red squares), 5 
wt-% (blue dots) and 2.4 wt-% (green down-pointing triangles). Results presented as 
mean ± S.D., n=3. 
5.3.2 Drug release and diffusivity  
The porosity and viscosity of the matrices were the most significant factors that controlled 
the diffusivity and release rate of encapsulated model compounds MZ and LZ, as no 
swelling was observed under test conditions. The experimental and simulated release 
profiles of MZ and LZ from different MCC matrices are presented in Figure 16. The 
experimental results up to 60 % release fitted well to theoretical predictions by an early 
times Fickian model. The release of neutral small molecule MZ was significantly faster 
from all tested matrices when compared to sustained release profiles obtained for a 
cationic and larger protein compound LZ (14.7 kDa). However, for both compounds the 
release rates from different MCC matrices were in the order MCC-D ˃ MCC ˃ MCC-L. 
The variances between different matrices were negligible for MZ and 92 – 100 % release 
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was reached at 48 h, depending on matrix, indicating full release. For LZ the release % 
was lower from all matrices and only 51 – 80 % was reached at 144 h. 
 
Figure 16. Experimental (mean ± S.D., n=3) and simulated cumulative release profiles of 
MZ (A) and LZ (B) from different matrices. Experimental results are presented as symbols 
MCC-D (black triangles), MCC (red squares) and MCC-L (blue diamond). Theoretical 
predictions of the unsteady-state form of Fick’s second law of diffusion, with early values 
of time when 0 ˂ Mt/M∞ ˂ 0.6, are marked as fits with solid lines.  
The diffusion coefficients were calculated in order to compare the diffusivities of model 
compounds inside MCC matrices (Table 8). Diffusion coefficients in mechanically 
dispersed MCC-D matrices for both compounds were higher than from non-dispersed 
MCC matrices. This may be due to a more homogenous MCC-D matrix where 
interconnected water capillaries are more evenly distributed, creating pathways for 
diffusion. MCC-L matrix most significantly prolonged the release rates of both 
compounds, which is reflected as the lowest diffusion coefficient values. It has been 
reported that the amorphous and relatively hydrophobic structure of lignin can be utilized 
for drug encapsulation [274]. Additionally, the MCC-L hydrogel had the highest viscosity. 
Both effects are expected to contribute to the slower release rate from the MCC-L 
matrices. 
Table 8. Diffusion coefficients for model compounds MZ and LZ in different MCC-based 
matrices. 
Matrix DMZ (×10-8 cm2 s-1) DLZ (×10-8 cm2 s-1) 
MCC 237 24 
MCC–D 269 38 
MCC–L 215 21 
 
In the previous study (II) with ANFC hydrogels, higher diffusion coefficients were 
obtained for MZ than for the MCC matrices. Therefore, the release rate control for MZ 
was even higher in case of MCC, at least with these cellulose contents. Conversely, the 
ANFC hydrogels provided, via electrostatic attractive forces, a greater control for LZ 
diffusion. Based on these results, MCC-based matrices may function similarly as ANFC in 
controlled release applications but certain variation is to be expected. 
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In summary, this study showed the applicability of novel MCC matrices for controlled 
drug release applications. Benefits of MCC (AaltoCell™ grades) are dispersability and 
colloidal stability for MCC-D and MCC-L. The mechanical treatment of MCC-D and
MCC-L was highly beneficial for enhancing the gel-forming ability. Furthermore, the bulk 
material processing allows adjustments of different solid MCC and lignin contents.
5.4 Bioadhesive NFC and ANFC films (III)  
Bioadhesive properties of buccal films enable the targeted-release of drugs directly into 
the mucosal membrane in the oral cavity. This drug delivery approach benefits from 
prolonged residence time of drug compounds at the target site and enables the localized 
treatment of oral diseases. Bioadhesive drug releasing NFC and ANFC films, potentially 
suitable for oral local drug delivery, were prepared by incorporating mucoadhesive 
biopolymers mucin, pectin and chitosan into the film structure. Films were prepared by 
simple liquid molding method that does not require chemical modifications, thus reducing 
processing steps and avoiding potentially toxic residues resulting from any chemical 
treatment. The suitability of the films, as mucoadhesive drug delivery platforms, was 
confirmed with several in vitro methods. 
5.4.1 Mucoadhesive film characterization 
NFC and ANFC were used as film forming materials whereas natural biopolymers pectin, 
mucin and chitosan were added to introduce mucoahesive properties. The mucoadhesive 
properties of films with NFC/ANFC in 10:1, 2:1, 1:1 mass ratios (wt/wt) to pectin, mucin 
and chitosan were evaluated with texture analysis measurements. The adhesiveness peak 
force (N) that describes the maximum force required to detach the analytical probe from 
the formulation was used as a measure of mucoadhesiveness. Highest mucoadhesive 
properties were obtained for NFC/ANFC films prepared with either pectin or mucin in 2:1 
mass ratio (Figure 17). These films were selected for futher mechanical strength and 
hydration capacity evaluations.  
Figure 17. Adhesiveness peak force for NFC and ANFC films combined with pectin, 
mucin and chitosan in 2:1 mass ratio (mean ± S.D., n=3). 
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The mechanical properties of different films (Table 9) were evaluated in terms of 
thickness (μm), tensile strength (MPa), elongation (%), Young’s modulus (GPa) and 
toughness (MJ/m3). The addition of mucoadhesive polymers increased the film thickness 
for both NFC and ANFC based films and altered the mechanical properties of films, 
resulting in higher mechanical strength for NFC-based films. For ANFC, the mechanical 
strength was reduced. Typical Young’s modulus and tensile strength values reported in the 
literature are 6 - 13 GPa and 129 - 214 MPa for NFC films and papers [76,77] and 10 GPa 
and 191 MPa for ANFC films [82]. However, the preparation method and film porosity 
have an effect on these values. The mechanical strength of the studied film compositions 
was not as strong as in previously published works in terms of tensile strength and 
Young’s modulus, but still suitable for handling of oral patches.
Table 9. Mechanical strength evaluation of bioadhesive films (mean ± S.D., n=5). Mass 
ratio of NFC/ANFC to mucin/pectin was 2:1. Abbreviation: YM = Young’s Modulus.
Formulation Film Thickness (μm)
Tensile strength 
(MPa)
Elongation 
(%)
YM 
(GPa)
Toughness 
(MJ/m3)
NFC 95.0 ± 11.4 83.0 ± 29.0 10.3 ± 3.0 3.6 ± 1.6 6.0 ± 4.0
ANFC 68.0 ± 5.6 65.8 ± 28.2 3.9 ± 2.0 5.8 ± 1.3 2.2 ± 1.4
NFC-Mucin 128.9 ± 29.5 82.7 ± 10.2 4.1 ± 2.1 5.9 ± 0.8 2.3 ± 1.3
ANFC-Mucin 129.2 ± 16.5 30.0 ± 3.8 4.1 ± 1.1 2.9 ± 0.1 0.9 ± 0.4
NFC-Pectin 161.4 ± 30.9 75.7 ± 11.7 3.9 ± 0.3 5.6 ± 1.0 2.0 ± 0.4
ANFC-Pectin 231.0 ± 47.7 27.0 ± 4.0 2.2 ± 1.1 2.8 ± 0.7 0.4 ± 0.3
The hydration properties and sufficient swelling are important properties for 
mucoadhesive formulations in addition to hydrogen bonding capacity [162]. Film pieces 
were immersed into pH 6.8 phosphate buffer, simulating the pH of oral cavity, for 15 s or 
5 h to evaluate the effect of fast or prolonged hydration (Table 10). Mass loss was used to 
evaluate the integrity of the films and indicated the amount of polymers eroded from the 
films. ANFC-based films had higher hydration capacity overall in fast and prolonged 
exposure. The carboxyl groups directly on ANFC fibers increase the hydrophilicity of the 
material in comparison to NFC, which explains the higher hydration capacity of ANFC 
films [275]. For mucin and pectin containing films, the hydration was lower at 15 s but 
more extensive at 5 h. Both polymers are very hydrophilic and capable of retaining large 
amounts of water, which likely caused the relatively high hydration % after long exposure 
to water [276]. The pectin containing films had higher hydration % and also mass loss % 
at 5 h when compared to mucin films. Therefore, erosion of the lamellar film structure 
occurred due to loss of pectin, but regardless of this the remaining film structure had high 
hydration. Based on the results, all bioadhesive polymer containing films had high 
hydration capacity required from mucoadhesive films. 
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Table 10. Hydration and mass loss of films after exposure to pH 6.8 phosphate buffer 
(mean ± S.D., n=3). Mass ratio of NFC/ANFC to mucin/pectin was 2:1.
Swelling studies in pH 6.8 phosphate buffer for 15 s or 5 h
Formulation
mg water/
mg film, 15 s
Hydration 
(%), 15 s
Mass loss
(%) 
mg water/
mg film, 5 h
Hydration 
(%), 5 h
Mass loss 
(%)
NFC 0.9 ± 0.1 89.9 ± 7.1 3.1 ± 0.8 1.8 ± 0.0 176.1 ± 4.3 0.6 ± 0.9
ANFC 1.7 ± 0.4 144 ± 12.1 4.6 ± 0.2 4.4 ± 0.1 436.8 ± 0.2 4.6 ± 0.2
NFC-Mucin 0.7 ± 0.3 52.3 ± 17.7 2.3 ± 0.3 4.3 ± 0.0 430.5 ± 3.8 12.2 ± 0.2
ANFC-Mucin 1.2 ± 0.1 123.5 ± 11.4 3.3 ± 1.2 5.2 ± 0.0 516.0 ± 3.4 12.5 ± 0.3
NFC-Pectin 0.7 ± 0.3 48.2 ± 9.8 4.3 ± 2.3 4.8 ± 0.0 467.8 ± 19.4 32.0 ± 1.3
ANFC-Pectin 0.5 ± 0.0 48.5 ± 0.6 4.6 ± 2.1 6.8 ± 0.0 682.7 ± 4.1 21.3 ± 0.5
5.4.2 Morphology and solid state characterization 
Metronidazole (MZ) containing films imaged with SEM revealed lamellar structures for 
the films (Figure 18). ANFC-based films were more densely packed with thicknesses of 
97.6 μm for ANFC-Mucin-MZ and 107.6 μm for ANFC-Pectin-MZ. Whereas, loosely 
packed lamellar layers were observed for NFC based films with total thicknesses of 238.8 
μm for NFC-Mucin-MZ and 228.2 μm for NFC-Pectin-MZ. 
Figure 18. SEM micrographs of 
ANFC/NFC films containing 
mucin/pectin, and metronidazole. Scale 
bar is 10 μm.
Similar thermal behavior was observed in DSC for all films with reduced melting points 
for MZ (Figure 19A). The reduced melting point of MZ may indicate interactions between 
the NFC/ANFC fibers and MZ. However, only for NFC-Pectin-MZ (151.8 °C) the melting 
point was significantly reduced. In the other films, the melting points were close to the 
161.9 ?C of pure MZ reference.  
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Figure 19. Solid state characterization of films with DSC (A) and Raman spectroscopy 
(B). Dashed line marks the melting point of pure MZ at 161.9 ?C (A). Characteristic 
Raman peaks of MZ are marked with dashed lines and arrows depict the broadening and 
shifting of MZ in the NFC-Pectin-MZ film (B). 
The characteristic Raman peaks for MZ at 1183 cm-1, 1267 cm-1, 1354 cm-1 and 1376 cm-1 
were observed in all films (Figure 19B). However, the broadening and shifting of the MZ 
peaks was only observed in the NFC-Pectin-MZ film. The differences between NFC-
Pectin-MZ films in relation to the other films may have been caused by binding 
interactions between pectin side chains and NFC, which consequently may alter the 
interactions of these polymers with MZ [277,278]. Intermolecular hydrogen bonding 
between pectin, NFC and MZ may have caused the peak widening at 1183 cm-1 and peak 
shifting of 1267 cm-1 to a lower wavenumber [279-283]. Also, at 1354 cm-1 and 1376 cm-1
the widening of MZ may indicate the formation of hydrogen bonds [279]. It has been 
reported that pectin-cellulose interactions may result in intermediate binding affinity of 
pectin into cellulose via neutral pectin side chains which reduces cellulose-cellulose 
interactions [14,284,285]. Also, hemicelluloses (e.g. xyloglycan) have binding affinity to 
pectin as well as cellulose microfibrils [278]. These factors may explain why NFC-Pectin-
MZ films had different solid state characteristics from the other films as NFC and pectin 
polymers may have favorable interactions for MZ encapsulation. ANFC fibers are coated 
with carboxyl groups which may reduce the binding interaction with pectin as there are 
fewer neutral binding sites in ANFC fiber structure and a lack of hemicellulose content. 
5.4.3 Drug release and toxicity 
The drug release properties of different films were evaluated at pH 6.8 in order to evaluate 
the effect of formulation on MZ release (Figure 20A). A relatively high burst release of 20 
- 40 % occurred for all formulations during the first 5 min. This phenomenon was likely 
attributed to the release of MZ on the surface of films. The mucin containing thinner films 
had overall a higher MZ release as opposed to the thicker pectin containing films. Overall, 
the highest drug release extent of 84.7 % was observed for NFC–Mucin-MZ, while the 
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smallest drug release of 59. 6 % was obtained with ANFC–Pectin-MZ. The drug release 
was slightly lower from ANFC films than NFC films with both mucoadhesive polymers. 
This could be explained with the apparent porosity observed in SEM images, where 
ANFC structure was denser than NFC. Furthermore, ANFC-based films had higher 
hydration capability and greater swelling in the vertical direction creating a larger barrier 
for diffusion. This was especially apparent for ANFC–Pectin-MZ films, which had the 
slowest drug release and where the swollen matrix was expected to create the longest 
diffusion path. 
Figure 20. Drug release profiles (mean ± S.D., n=3) of MZ from different mucoadhesive 
formulations (A). TR146 cytotoxicity assays (mean ± S.D., n=4) on different mucoadhesive 
films with and without MZ after 24 h incubation.
All films had rather suitable drug release profiles for MZ. Especially in buccal drug 
delivery applications, fast drug release from the film into the mucosal membrane would be 
advantageous. Mucoadhesion combined with fast drug release properties could be used to 
promote site-specific drug delivery of MZ for e.g. treatment of periodontal diseases in the 
oral cavity. Human TR146 cell line was used in cytotoxicity studies of film patches 
(Figure 20B). The cell line has been previously used as a tool to model human buccal 
epithelium effectively [176,177]. Patches without MZ had no significant cytotoxic effects 
on the cells. MZ containing patches showed slight cytotoxic effect, which is probably due 
to the high local concentration of MZ during the experiment. It has been previously shown 
that above 5 mM concentration, MZ may induce cytotoxic effects [286]. Therefore, the 
film forming polymers and incorporated mucoadhesive polymers were shown to be 
nontoxic on TR146 cells. 
In summary, this study demonstrated that NFC and ANFC can be used as film forming 
materials for mucoadhesive pharmaceutical patches. Furthermore, the patches consisting 
of all natural polymers had high mucoadhesive properties in combination with good 
mechanical, water retention and drug release properties as well as low toxicity. 
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6 Conclusions and future outlook  
  
In this thesis, the applicability of nanofibrillar cellulose (NFC and ANFC) as novel 
pharmaceutical excipient was evaluated in a variety of formulations ranging from 
emulsions and hydrogels/reconstructed hydrogels to mucoadhesive films. The innate 
structural properties such as high mechanical strength, water retention capability, 
pseudoplastic properties and high surface area were utilized for the encapsulation of active 
materials.   
Emulsification with a relatively simple sonication method was used to produce HFBII-
NFC and HFBII-ANFC emulsions for immediate and sustained release applications 
respectively. It was demonstrated that tunable drug release properties were achieved with 
the choice of NFC/ANFC fiber grade. ANFC fibers created a higher diffusion barrier for 
drug release together with the HFBII coating on the oil droplets, whereas longer NFC 
fibers did not control the drug release as significantly, most likely due to negligible 
interactions with HFBII. However, both nanofibrillar cellulose grades, NFC and ANFC, 
could be used to increase the storage stability of emulsions when combined with HFBII. 
The concentrations of HFBII/NFC/ANFC required for stabilization were extremely low at 
0.1 - 0.15 %. As synthetic polymers are traditionally used for the stabilization of 
pharmaceutical emulsions, these new biopolymers with low toxicity and good 
biocompatibility could provide a viable option for formulation development in the future. 
Also, micro-dosing of potent drugs with this type of emulsions through the oral route 
could be further explored. Furthermore, enhancing the solubility of other poorly soluble 
drugs with these emulsions at a higher oil phase volume could be explored for controlled 
release applications of poorly soluble BCS class II drugs. In the future, however the 
stability of the formulations in the aqueous environment of gastrointestinal tract should be 
defined as for example proteases may affect the stability of protein stabilized formulations 
and consequent bioavailability. 
The ANFC hydrogels proved to be suitable for the freeze-drying and consequent 
rehydration without significant loss on rheological properties or drug release properties. 
The manufacturing of dry forms of ANFC and NFC has been a challenge with regard to 
preserving the nano-scale structure as usually the fibers tend to aggregate during drying 
due to hornification. Here the structure of ANFC was effectively preserved in the presence 
of commonly used cryo- lyoprotectants trehalose and PEG6000. This is a highly desirable 
feature for manufacturing of pharmaceutical dosage forms as the shelf-life of hydrolysis 
sensitive compounds can be increased by the dry state of an aerogel. The high fiber 
content of 3 % and 6.5 % ANFC hydrogels was effective in controlling the release of large 
molecular weight compounds, whereas a moderate control was obtained for small 
molecules. The results indicate the suitability of ANFC hydrogels for controlled delivery 
of several types of molecules. In the future, the hydrogels could be used as such directly 
on topical administration of therapeutic molecules for example in wound healing 
applications, where the high water content of the hydrogel combined with antibiotics, 
corticosteroids or growth factors could enhance the healing rate. The ANFC hydrogel as 
well as aerogel matrices would likely perform well also in matrix systems as structurally 
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the hydrogel and aerogel matrices themselves provide direct control for the drug release. 
Furthermore, the applicability of ANFC hydrogels could be explored in reservoir type 
drug delivery systems such as osmotic pump capsules where the water absorption 
capability of ANFC could be utilized in combination with a rate controlling membrane.  
The comparable study with new MCC hydrogel dispersions showed that the non-
dispersed, dispersed and lignin containing MCC grades proved to be effective in 
controlling the drug release of small and large molecules. These new MCC grades showed 
high potential in terms of usability in controlled drug release applications as hydrogel 
platforms in similar manner to ANFC hydrogels. However, as the material is relatively 
new, a considerable effort should be focused on exploring the full potential of these new 
MCC grades in drug release applications in the future. Especially, the colloidally stable 
MCC-D and MCC-L should be explored as stabilizers for dispersions and emulsions as 
well as for spray-dried and freeze-dried dosage forms as structurally these grades provide 
high encapsulation potential for therapeutic compounds. The dispersability and higher 
colloidal stability of these new grades, when compared to conventional Avicel grades, 
could be utilized in multiple different pharmaceutical dosage forms in the future. 
The bioadhesive NFC and ANFC films prepared with natural adhesive polymers mucin, 
pectin and chitosan had high hydration capability, good mucoadhesion strength and 
adequate mechanical properties. Furthermore, the fast drug release properties obtained for 
encapsulated antibiotic metronidazole combined with the bioadhesive properties and low 
toxicity showed high potential for buccal drug delivery applications. These films were 
prepared with a simple liquid molding method without any requirement for further 
chemical modification. The quality of the films could be enhanced even further in the 
future with other processing techniques such as filtration or hot pressing, ensuring higher 
manufacturability. Furthermore, these films could provide a platform for local delivery of 
therapeutic compounds into other mucosal tissues besides the oral cavity. 
As a summary, this thesis clearly demonstrated the applicability of new nano- and 
microcellulose-based products, namely NFC, ANFC and a new grade of MCC, as 
pharmaceutical excipients for many types of dosage forms. The structural properties of
these natural biopolymers enable their versatile use, and future studies in the field of 
formulation development will certainly advance their utilization as components in
conventional and novel drug delivery systems. 
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